BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567. [PMID: 25428504 DOI: 10.1038/nature14011] [Cited by in Crossref: 2878] [Cited by in F6Publishing: 2815] [Article Influence: 411.1] [Reference Citation Analysis]
Number Citing Articles
1 Wang W, Shen G, Wu S, Song S, Ni Y, Suo Z, Meng X, Li D, Zhou L, Hao R, Zhao Y, Bai L, Hou L, Liu B, Liu G. PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. Oncotarget 2017;8:50782-91. [PMID: 28881603 DOI: 10.18632/oncotarget.15006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kersten K, Salvagno C, de Visser KE. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol 2015;6:516. [PMID: 26500653 DOI: 10.3389/fimmu.2015.00516] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
3 Friedrich J, Heim L, Trufa DI, Sirbu H, Rieker RJ, Chiriac MT, Finotto S. STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNFα mediated immune responses in a model of NSCLC. Oncotarget 2018;9:37157-72. [PMID: 30647851 DOI: 10.18632/oncotarget.26441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
4 Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 2015;26:1824-9. [PMID: 25888611 DOI: 10.1093/annonc/mdv182] [Cited by in Crossref: 128] [Cited by in F6Publishing: 121] [Article Influence: 18.3] [Reference Citation Analysis]
5 Chae YK, Davis AA, Raparia K, Agte S, Pan A, Mohindra N, Villaflor V, Giles F. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. Clin Lung Cancer 2019;20:88-96.e6. [PMID: 30425022 DOI: 10.1016/j.cllc.2018.09.008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
6 Yoneshima Y, Ijichi K, Anai S, Ota K, Otsubo K, Iwama E, Tanaka K, Oda Y, Nakanishi Y, Okamoto I. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Lung Cancer 2018;118:36-40. [PMID: 29572000 DOI: 10.1016/j.lungcan.2018.01.024] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 10.3] [Reference Citation Analysis]
7 Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74-80. [PMID: 25838376 DOI: 10.1126/science.aaa6204] [Cited by in Crossref: 939] [Cited by in F6Publishing: 879] [Article Influence: 134.1] [Reference Citation Analysis]
8 Wu J, Zhang A, Li L, Liu S, Yang F, Yang R. Meta-analysis of the Efficacy and Tolerability of Immune Checkpoint Inhibitors Combined With Chemotherapy in First-line Treatment of Small Cell Lung Cancer. Clin Ther 2021;43:582-593.e2. [PMID: 33509647 DOI: 10.1016/j.clinthera.2020.12.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Takamochi K, Hara K, Hayashi T, Kohsaka S, Takahashi F, Suehara Y, Suzuki K. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. Lung Cancer 2021;161:163-70. [PMID: 34600407 DOI: 10.1016/j.lungcan.2021.09.011] [Reference Citation Analysis]
10 Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945-950. [PMID: 25981182 DOI: 10.1111/cas.12695] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
11 Twitty CG, Huppert LA, Daud AI. Prognostic Biomarkers for Melanoma Immunotherapy. Curr Oncol Rep 2020;22:25. [PMID: 32048065 DOI: 10.1007/s11912-020-0886-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Kang J, Jeong JH, Hwang HS, Lee SS, Park DH, Oh DW, Song TJ, Kim KH, Hwang S, Hwang DW, Kim SC, Park JH, Hong SM, Kim KP, Ryoo BY, Yoo C. Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. Cancer Res Treat 2020;52:594-603. [PMID: 32019287 DOI: 10.4143/crt.2019.493] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
13 Babačić H, Lehtiö J, Pico de Coaña Y, Pernemalm M, Eriksson H. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma. J Immunother Cancer 2020;8:e000204. [PMID: 32457125 DOI: 10.1136/jitc-2019-000204] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
14 Dahan R, Sega E, Engelhardt J, Selby M, Korman A, Ravetch J. FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell 2015;28:285-95. [DOI: 10.1016/j.ccell.2015.08.004] [Cited by in Crossref: 155] [Cited by in F6Publishing: 145] [Article Influence: 22.1] [Reference Citation Analysis]
15 Kerioui M, Mercier F, Bertrand J, Tardivon C, Bruno R, Guedj J, Desmée S. Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. Stat Med 2020;39:4853-68. [PMID: 33032368 DOI: 10.1002/sim.8756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Tsuchiya T, Someya M, Takada Y, Hasegawa T, Kitagawa M, Fukushima Y, Gocho T, Hori M, Nakata K, Hirohashi Y, Torigoe T, Saito T, Sakata KI. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. Strahlenther Onkol 2020;196:725-35. [PMID: 31953603 DOI: 10.1007/s00066-019-01571-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
17 Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H, Uemura K, Morita S, Yamamoto N. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Lung Cancer 2019;128:113-9. [PMID: 30642442 DOI: 10.1016/j.lungcan.2018.12.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
18 Spyrou N, Vallianou N, Kadillari J, Dalamaga M. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. Seminars in Cancer Biology 2021;73:356-76. [DOI: 10.1016/j.semcancer.2021.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Luo Y, Eran A, Palmer N, Avillach P, Levy-Moonshine A, Szolovits P, Kohane IS. A multidimensional precision medicine approach identifies an autism subtype characterized by dyslipidemia. Nat Med 2020;26:1375-9. [PMID: 32778826 DOI: 10.1038/s41591-020-1007-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
20 Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer 2016;57:91-103. [PMID: 26901614 DOI: 10.1016/j.ejca.2015.12.033] [Cited by in Crossref: 79] [Cited by in F6Publishing: 88] [Article Influence: 13.2] [Reference Citation Analysis]
21 Sjödahl G, Jackson CL, Bartlett JM, Siemens DR, Berman DM. Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. J Pathol 2019;247:563-73. [PMID: 30604486 DOI: 10.1002/path.5230] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
22 Wang Y, Chen H, Zhang T, Yang X, Zhong J, Wang Y, Chi Y, Wu M, An T, Li J, Zhao X, Dong Z, Wang Z, Zhao J, Zhuo M, Huang J. Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. Ann Transl Med 2021;9:33. [PMID: 33553326 DOI: 10.21037/atm-20-1513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Liu M, Sun Q, Wei F, Ren X. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors. Cancer Biol Med 2020;17:626-39. [PMID: 32944395 DOI: 10.20892/j.issn.2095-3941.2020.0112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Sun SY. Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Transl Oncol 2020;13:100847. [PMID: 32854033 DOI: 10.1016/j.tranon.2020.100847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Sundararajan S, Vogelzang NJ. Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon? Future Oncology 2015;11:2299-306. [DOI: 10.2217/fon.15.162] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
26 Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, Kim HM, Raben D, Tan AC, Heasley L, Clambey E, Nemenoff R, Karam SD. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clin Cancer Res 2018;24:5368-80. [PMID: 30042205 DOI: 10.1158/1078-0432.CCR-18-1038] [Cited by in Crossref: 83] [Cited by in F6Publishing: 49] [Article Influence: 20.8] [Reference Citation Analysis]
27 Jain P, Jain C, Velcheti V. Role of immune-checkpoint inhibitors in lung cancer. Ther Adv Respir Dis 2018;12:1753465817750075. [PMID: 29385894 DOI: 10.1177/1753465817750075] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
28 O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151-167. [PMID: 30523282 DOI: 10.1038/s41571-018-0142-8] [Cited by in Crossref: 328] [Cited by in F6Publishing: 322] [Article Influence: 109.3] [Reference Citation Analysis]
29 Xiao X, Mo H, Tu K. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression. Int Immunopharmacol 2020;89:107043. [PMID: 33039961 DOI: 10.1016/j.intimp.2020.107043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Desbois M, Udyavar AR, Ryner L, Kozlowski C, Guan Y, Dürrbaum M, Lu S, Fortin JP, Koeppen H, Ziai J, Chang CW, Keerthivasan S, Plante M, Bourgon R, Bais C, Hegde P, Daemen A, Turley S, Wang Y. Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nat Commun 2020;11:5583. [PMID: 33149148 DOI: 10.1038/s41467-020-19408-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
31 Zhao Y, Lee CK, Lin CH, Gassen RB, Xu X, Huang Z, Xiao C, Bonorino C, Lu LF, Bui JD, Hui E. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity 2019;51:1059-1073.e9. [PMID: 31757674 DOI: 10.1016/j.immuni.2019.11.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 23.7] [Reference Citation Analysis]
32 Wang Q, Xie B, Liu S, Shi Y, Tao Y, Xiao D, Wang W. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol 2021;12:773168. [PMID: 35003090 DOI: 10.3389/fimmu.2021.773168] [Reference Citation Analysis]
33 Hu ZY, Huang WY, Zhang L, Huang B, Chen SC, Li XL. Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis. Ann Transl Med 2020;8:1172. [PMID: 33241021 DOI: 10.21037/atm-20-5865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Stampouloglou E, Cheng N, Federico A, Slaby E, Monti S, Szeto GL, Varelas X. Yap suppresses T-cell function and infiltration in the tumor microenvironment. PLoS Biol 2020;18:e3000591. [PMID: 31929526 DOI: 10.1371/journal.pbio.3000591] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
35 Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015;3:267. [PMID: 26605313 DOI: 10.3978/j.issn.2305-5839.2015.10.27] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
36 Tran L, Theodorescu D. Determinants of Resistance to Checkpoint Inhibitors. Int J Mol Sci 2020;21:E1594. [PMID: 32111080 DOI: 10.3390/ijms21051594] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
37 Yu W, Wang Y, Zhu J, Jin L, Liu B, Xia K, Wang J, Gao J, Liang C, Tao H. Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy. Biomaterials 2019;192:128-39. [PMID: 30448697 DOI: 10.1016/j.biomaterials.2018.11.019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
38 Takada K, Okamoto T, Shoji F, Shimokawa M, Akamine T, Takamori S, Katsura M, Suzuki Y, Fujishita T, Toyokawa G, Morodomi Y, Okano S, Oda Y, Maehara Y. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. Journal of Thoracic Oncology 2016;11:1879-90. [DOI: 10.1016/j.jtho.2016.06.006] [Cited by in Crossref: 98] [Cited by in F6Publishing: 107] [Article Influence: 16.3] [Reference Citation Analysis]
39 Zavala VA, Kalergis AM. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015;145:182-201. [PMID: 25826229 DOI: 10.1111/imm.12459] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
40 Li M, Kaili D, Shi L. Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 19-37 [DOI: 10.4251/wjgo.v14.i1.19] [Reference Citation Analysis]
41 Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 2015;67:4-17. [PMID: 25749122 DOI: 10.1016/j.molimm.2015.02.009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 134] [Article Influence: 18.9] [Reference Citation Analysis]
42 Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, Lion E. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Front Immunol 2018;9:394. [PMID: 29599770 DOI: 10.3389/fimmu.2018.00394] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
43 Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD. Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell 2018;33:1017-1032.e7. [PMID: 29894689 DOI: 10.1016/j.ccell.2018.05.009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 23.3] [Reference Citation Analysis]
44 Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol 2019;40:511-23. [PMID: 31053497 DOI: 10.1016/j.it.2019.04.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 24.7] [Reference Citation Analysis]
45 de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B. TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell 2018;33:60-74.e6. [PMID: 29316433 DOI: 10.1016/j.ccell.2017.11.019] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 28.3] [Reference Citation Analysis]
46 Gerard CL, Delyon J, Wicky A, Homicsko K, Cuendet MA, Michielin O. Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treat Rev 2021;101:102227. [PMID: 34656019 DOI: 10.1016/j.ctrv.2021.102227] [Reference Citation Analysis]
47 Lehrke HD, Graham RP, McWilliams RR, Lam-Himlin DM, Smyrk TC, Jenkins S, Dong H, Zhang L. Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. Am J Clin Pathol. 2017;148:441-449. [PMID: 29069274 DOI: 10.1093/ajcp/aqx092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
48 Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology 2017;6:e1344805. [PMID: 29123955 DOI: 10.1080/2162402X.2017.1344805] [Cited by in Crossref: 79] [Cited by in F6Publishing: 42] [Article Influence: 15.8] [Reference Citation Analysis]
49 Zhang D, Huang J, Zhang C, Guan Y, Guo Q. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer]. Zhongguo Fei Ai Za Zhi 2019;22:369-79. [PMID: 31196371 DOI: 10.3779/j.issn.1009-3419.2019.06.07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
50 Huynh TG, Morales-Oyarvide V, Campo MJ, Gainor JF, Bozkurtlar E, Uruga H, Zhao L, Gomez-Caraballo M, Hata AN, Mark EJ, Lanuti M, Engelman JA, Mino-Kenudson M. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. J Thorac Oncol 2016;11:1869-78. [PMID: 27568346 DOI: 10.1016/j.jtho.2016.08.134] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
51 Rangamuwa K, Leong T, Weeden C, Asselin-Labat ML, Bozinovski S, Christie M, John T, Antippa P, Irving L, Steinfort D. Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Transl Lung Cancer Res 2021;10:2842-57. [PMID: 34295682 DOI: 10.21037/tlcr-20-1075] [Reference Citation Analysis]
52 Borrie AE, Maleki Vareki S. T Lymphocyte–Based Cancer Immunotherapeutics. Biology of T Cells - Part A. Elsevier; 2018. pp. 201-76. [DOI: 10.1016/bs.ircmb.2018.05.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
53 Liu SL, Bian LJ, Liu ZX, Chen QY, Sun XS, Sun R, Luo DH, Li XY, Xiao BB, Yan JJ, Lu ZJ, Yan SM, Yuan L, Tang LQ, Li JM, Mai HQ. Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma. J Immunother Cancer 2020;8:e000205. [PMID: 32303611 DOI: 10.1136/jitc-2019-000205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
54 Pan C, Liu H, Robins E, Song W, Liu D, Li Z, Zheng L. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol 2020;13:29. [PMID: 32245497 DOI: 10.1186/s13045-020-00862-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
55 Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, Guo J, Peng H, Chen M, Fu YX, Tang H. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun 2020;11:4835. [PMID: 32973173 DOI: 10.1038/s41467-020-18570-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 21.5] [Reference Citation Analysis]
56 Feng Z, Puri S, Moudgil T, Wood W, Hoyt CC, Wang C, Urba WJ, Curti BD, Bifulco CB, Fox BA. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer 2015;3:47. [PMID: 26500776 DOI: 10.1186/s40425-015-0091-z] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 11.1] [Reference Citation Analysis]
57 Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Guérin M, Biton J, Ouakrim H, Régnier F, Lupo A, Alifano M, Damotte D, Donnadieu E. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A 2018;115:E4041-50. [PMID: 29632196 DOI: 10.1073/pnas.1720948115] [Cited by in Crossref: 246] [Cited by in F6Publishing: 243] [Article Influence: 61.5] [Reference Citation Analysis]
58 Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev 2020;84:101977. [PMID: 32018128 DOI: 10.1016/j.ctrv.2020.101977] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
59 Ung C, Kockx MM. Challenges & Perspectives of Immunotherapy Biomarkers & The HistoOncoImmune™ Methodology. Expert Review of Precision Medicine and Drug Development 2016;1:9-24. [DOI: 10.1080/23808993.2016.1140005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
60 Ahuja J, Shroff GS, Strange CD, Vlahos I, Benveniste MFK, Truong MT. Pearls and Pitfalls in the Imaging of Targeted Therapy and Immunotherapy in Lung Cancer. Semin Ultrasound CT MR 2021;42:552-62. [PMID: 34895611 DOI: 10.1053/j.sult.2021.04.015] [Reference Citation Analysis]
61 Lemos H, Huang L, Prendergast GC, Mellor AL. Immune control by amino acid catabolism during tumorigenesis and therapy. Nat Rev Cancer 2019;19:162-75. [PMID: 30696923 DOI: 10.1038/s41568-019-0106-z] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 22.3] [Reference Citation Analysis]
62 Kurino T, Matsuda R, Terui A, Suzuki H, Kokubo T, Uehara T, Arano Y, Hisaka A, Hatakeyama H. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. J Immunother Cancer 2020;8:e000400. [PMID: 32041818 DOI: 10.1136/jitc-2019-000400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 Nishimori A, Konnai S, Okagawa T, Maekawa N, Ikebuchi R, Goto S, Sajiki Y, Suzuki Y, Kohara J, Ogasawara S, Kato Y, Murata S, Ohashi K. In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. PLoS One 2017;12:e0174916. [PMID: 28445479 DOI: 10.1371/journal.pone.0174916] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
64 Denton AE, Roberts EW, Fearon DT. Stromal Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2018;1060:99-114. [PMID: 30155624 DOI: 10.1007/978-3-319-78127-3_6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 16.7] [Reference Citation Analysis]
65 Youn JW, Hur SY, Woo JW, Kim YM, Lim MC, Park SY, Seo SS, No JH, Kim BG, Lee JK, Shin SJ, Kim K, Chaney MF, Choi YJ, Suh YS, Park JS, Sung YC. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol 2020;21:1653-60. [PMID: 33271094 DOI: 10.1016/S1470-2045(20)30486-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
66 Ota Y, Takahari D, Suzuki T, Osumi H, Nakayama I, Oki A, Wakatsuki T, Ichimura T, Ogura M, Shinozaki E, Suenaga M, Chin K, Yamaguchi K. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemother Pharmacol 2020;85:265-72. [PMID: 31907646 DOI: 10.1007/s00280-019-04023-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
67 Lim JS, Sundar R, Chénard-poirier M, Lopez J, Yap TA. Emerging biomarkers for PD-1 pathway cancer therapy. Biomarkers in Medicine 2017;11:53-67. [DOI: 10.2217/bmm-2016-0228] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
68 Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Muley T, Herth F, Penzel R, Warth A, Winter H, Fröhling S, Peters S, Swanton C, Thomas M, Schirmacher P, Budczies J, Stenzinger A. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. J Thorac Oncol 2019;14:1935-47. [PMID: 31349062 DOI: 10.1016/j.jtho.2019.07.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
69 Segovia-Mendoza M, Romero-Garcia S, Lemini C, Prado-Garcia H. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. J Immunol Res 2021;2021:6668573. [PMID: 33506060 DOI: 10.1155/2021/6668573] [Reference Citation Analysis]
70 De Meulenaere A, Vermassen T, Aspeslagh S, Huvenne W, Van Dorpe J, Ferdinande L, Rottey S. Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. Oral Oncology 2017;70:34-42. [DOI: 10.1016/j.oraloncology.2017.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
71 Seow DYB, Yeong JPS, Lim JX, Chia N, Lim JCT, Ong CCH, Tan PH, Iqbal J. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. Breast Cancer Res Treat 2020;180:369-77. [PMID: 32034580 DOI: 10.1007/s10549-020-05548-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
72 Velaga R, Sugimoto M. Future Paradigm of Breast Cancer Resistance and Treatment. In: Prosperi JR, editor. Resistance to Targeted Therapies in Breast Cancer. Cham: Springer International Publishing; 2017. pp. 155-78. [DOI: 10.1007/978-3-319-70142-4_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
73 Rajani KR, Vile RG. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses 2015;7:5889-901. [PMID: 26580645 DOI: 10.3390/v7112914] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
74 González S, Volkova N, Beer P, Gerstung M. Immuno-oncology from the perspective of somatic evolution. Semin Cancer Biol 2018;52:75-85. [PMID: 29223477 DOI: 10.1016/j.semcancer.2017.12.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
75 Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol 2021;32:384-94. [PMID: 33309774 DOI: 10.1016/j.annonc.2020.12.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
76 Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y, Kato H, Morita A, Asai J, Katoh N, Yokota K, Akiyama M, Ihn H, Fukushima S, Nakamura Y. Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology 2016;5:e1204507. [PMID: 27757299 DOI: 10.1080/2162402X.2016.1204507] [Cited by in Crossref: 74] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
77 Jiang Z, Pan Z, Ren X. [Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2017;20:138-42. [PMID: 28228226 DOI: 10.3779/j.issn.1009-3419.2017.02.09] [Reference Citation Analysis]
78 Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 2020;37:720-734.e13. [PMID: 32359397 DOI: 10.1016/j.ccell.2020.04.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
79 Delafoy A, Uguen A, Lemasson G, Conan-Charlet V, Pradier O, Lucia F, Schick U. PD-L1 expression in recurrent head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2021. [PMID: 33796940 DOI: 10.1007/s00405-021-06777-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Miwa S, Nojima T, Alomesen AA, Ikeda H, Yamamoto N, Nishida H, Hayashi K, Takeuchi A, Igarashi K, Higuchi T, Yonezawa H, Araki Y, Morinaga S, Asano Y, Tsuchiya H. Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial. Clin Transl Oncol 2021;23:1620-9. [PMID: 33635466 DOI: 10.1007/s12094-021-02559-z] [Reference Citation Analysis]
81 Yang K, Xu J, Liu Q, Li J, Xi Y. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia. Pathol Res Pract 2019;215:265-71. [PMID: 30466764 DOI: 10.1016/j.prp.2018.10.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
82 Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J Immunother Cancer 2019;7:18. [PMID: 30678715 DOI: 10.1186/s40425-018-0489-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
83 Cooper WA, Lantuejoul S, Mino-Kenudson M. Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC-Is Multiplex Immunohistochemistry or Immunofluorescence the Answer? J Thorac Oncol 2021;16:1247-9. [PMID: 34304853 DOI: 10.1016/j.jtho.2021.06.007] [Reference Citation Analysis]
84 Cui S, Su X, Dong L, Qian J, Ye L, Zhang T, Fu H, Han H, Huang J, Yao Y, Gu Y, Jiang L. Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. J Cancer 2017;8:4075-82. [PMID: 29187883 DOI: 10.7150/jca.21415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
85 Acres B, Lacoste G, Limacher JM. Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour. Curr Top Microbiol Immunol 2017;405:79-97. [PMID: 25702159 DOI: 10.1007/82_2015_429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
86 Muthuswamy R, Corman JM, Dahl K, Chatta GS, Kalinski P. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells. Prostate 2016;76:1095-105. [PMID: 27199259 DOI: 10.1002/pros.23194] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
87 Carrizosa DR, Gold KA. New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2015;4:553-9. [PMID: 26629424 DOI: 10.3978/j.issn.2218-6751.2015.06.05] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
88 Kim JY, Lee E, Park K, Park WY, Jung HH, Ahn JS, Im YH, Park YH. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. Oncotarget 2017;8:47400-11. [PMID: 28537889 DOI: 10.18632/oncotarget.17653] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
89 Zhou S, Zhao X, Yang Z, Yang R, Chen C, Zhao K, Wang W, Ma Y, Zhang Q, Wang X. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma. Int J Cancer 2019;145:763-74. [PMID: 31044422 DOI: 10.1002/ijc.32379] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
90 Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, Callahan MK, Atkins MB, Sharon E, Antonia SJ, West P, Gravell AE; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration. The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectr 2018;2:pky021. [PMID: 30057972 DOI: 10.1093/jncics/pky021] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
91 Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, Baratti D, Camisaschi C, Villa A, Vergani B, Rivoltini L, Pilotti S, Castelli C. Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types. J Immunol Res 2018;2018:5804230. [PMID: 30510965 DOI: 10.1155/2018/5804230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
92 Hsu ML, Naidoo J. Principles of Immunotherapy in Non-Small Cell Lung Cancer. Thorac Surg Clin 2020;30:187-98. [PMID: 32327177 DOI: 10.1016/j.thorsurg.2020.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
93 Guo W, Wang P, Li N, Shao F, Zhang H, Yang Z, Li R, Gao Y, He J. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget 2018;9:13920-33. [PMID: 29568405 DOI: 10.18632/oncotarget.23810] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
94 Brcic L, Klikovits T, Megyesfalvi Z, Mosleh B, Sinn K, Hritcu R, Laszlo V, Cufer T, Rozman A, Kern I, Mohorcic K, Jakopovic M, Samarzija M, Seiwerth S, Kolek V, Fischer O, Jakubec P, Škarda J, Gieszer B, Hegedus B, Fillinger J, Renyi-Vamos F, Buder A, Bilecz A, Berger W, Grusch M, Hoetzenecker K, Klepetko W, Hoda MA, Filipits M, Dome B. Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study. Transl Lung Cancer Res 2021;10:1594-607. [PMID: 34012777 DOI: 10.21037/tlcr-20-1114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Gao J, Zhang H, Zhou F, Hou B, Chen M, Xie Z, Yu H. Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition. Chinese Chemical Letters 2021;32:1929-36. [DOI: 10.1016/j.cclet.2020.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Davis RS. Roles for the FCRL6 Immunoreceptor in Tumor Immunology. Front Immunol 2020;11:575175. [PMID: 33162991 DOI: 10.3389/fimmu.2020.575175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Medina PJ, Adams VR. PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. Pharmacotherapy 2016;36:317-34. [PMID: 26822752 DOI: 10.1002/phar.1714] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
98 Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin Pathol 2018;71:189-94. [PMID: 29097600 DOI: 10.1136/jclinpath-2017-204853] [Cited by in Crossref: 94] [Cited by in F6Publishing: 104] [Article Influence: 18.8] [Reference Citation Analysis]
99 You W, Shang B, Sun J, Liu X, Su L, Jiang S. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncol Rep 2020;44:424-37. [PMID: 32627031 DOI: 10.3892/or.2020.7643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
100 Loo K, Daud AI. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs. Cancer J. 2017;23:3-9. [PMID: 28114249 DOI: 10.1097/ppo.0000000000000238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
101 Lu LC, Lee YH, Chang CJ, Shun CT, Fang CY, Shao YY, Liu TH, Cheng AL, Hsu CH. Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer. 2019;8:110-120. [PMID: 31019901 DOI: 10.1159/000489021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
102 Wang D, Wang T, Yu H, Feng B, Zhou L, Zhou F, Hou B, Zhang H, Luo M, Li Y. Engineering nanoparticles to locally activate T cells in the tumor microenvironment. Sci Immunol 2019;4:eaau6584. [PMID: 31300478 DOI: 10.1126/sciimmunol.aau6584] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 42.0] [Reference Citation Analysis]
103 Nakao S, Arai Y, Tasaki M, Yamashita M, Murakami R, Kawase T, Amino N, Nakatake M, Kurosaki H, Mori M, Takeuchi M, Nakamura T. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Sci Transl Med 2020;12:eaax7992. [PMID: 31941828 DOI: 10.1126/scitranslmed.aax7992] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 39.0] [Reference Citation Analysis]
104 Zhang J, Wolfgang CL, Zheng L. Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel). 2018;10. [PMID: 29385739 DOI: 10.3390/cancers10020039] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
105 Shibahara D, Tanaka K, Iwama E, Kubo N, Ota K, Azuma K, Harada T, Fujita J, Nakanishi Y, Okamoto I. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. J Thorac Oncol 2018;13:926-37. [PMID: 29596910 DOI: 10.1016/j.jtho.2018.03.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
106 Wu J, Li X, Teng X, Rubin DL, Napel S, Daniel BL, Li R. Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Res 2018;20:101. [PMID: 30176944 DOI: 10.1186/s13058-018-1039-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
107 Wu Y, Biswas D, Swanton C. Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Semin Cancer Biol 2021:S1044-579X(21)00042-0. [PMID: 33631295 DOI: 10.1016/j.semcancer.2021.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 London NR Jr, Rooper LM, Bishop JA, Xu H, Bernhardt LJ, Ishii M, Hann CL, Taube JM, Izumchenko E, Gaykalova DA, Gallia GL. Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. World Neurosurg 2020;135:e187-93. [PMID: 31785431 DOI: 10.1016/j.wneu.2019.11.112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
109 Bunn PA Jr. Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. J Clin Oncol 2017;35:243-52. [PMID: 28056194 DOI: 10.1200/JCO.2016.70.4064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
110 Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract 2016;3:11. [PMID: 27904752 DOI: 10.1186/s40661-016-0033-6] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 14.8] [Reference Citation Analysis]
111 Takeda Y, Azuma M, Funami K, Shime H, Matsumoto M, Seya T. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide. Front Immunol 2018;9:496. [PMID: 29593736 DOI: 10.3389/fimmu.2018.00496] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
112 Placke JM, Soun C, Bottek J, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Pfeiffer C, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Zimmer L, Livingstone E, Becker JC, Lodde G, Sucker A, Griewank K, Horn S, Hadaschik E, Roesch A, Schadendorf D, Engel DR, Ugurel S. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. Front Oncol 2021;11:741993. [PMID: 34621681 DOI: 10.3389/fonc.2021.741993] [Reference Citation Analysis]
113 Mino-Kenudson M. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol Med 2016;13:157-70. [PMID: 27458525 DOI: 10.20892/j.issn.2095-3941.2016.0009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
114 Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi H, Maruyama R, Imai K, Yamamoto H, Shinomura Y. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016; 22(2): 557-566 [PMID: 26811607 DOI: 10.3748/wjg.v22.i2.557] [Cited by in CrossRef: 154] [Cited by in F6Publishing: 138] [Article Influence: 25.7] [Reference Citation Analysis]
115 Safi S, Yamauchi Y, Hoffmann H, Weichert W, Jost PJ, Winter H, Muley T, Beckhove P. Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-Naïve Patients with Resectable Non-Small-Cell Lung Cancer. Cancers (Basel) 2020;12:E3496. [PMID: 33255425 DOI: 10.3390/cancers12123496] [Reference Citation Analysis]
116 . Cancer Immunotherapy Scores Again. Cell 2015;160:7-9. [DOI: 10.1016/j.cell.2014.12.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
117 Uryvaev A, Passhak M, Hershkovits D, Sabo E, Bar-sela G. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol 2018;35. [DOI: 10.1007/s12032-018-1080-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 14.3] [Reference Citation Analysis]
118 Kruger S, Legenstein ML, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 2017;6:e1310358. [PMID: 28638732 DOI: 10.1080/2162402X.2017.1310358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
119 Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy 2015;7:777-92. [PMID: 26250412 DOI: 10.2217/imt.15.49] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
120 Zhang F, Qi X, Wang X, Wei D, Wu J, Feng L, Cai H, Wang Y, Zeng N, Xu T, Zhou A, Zheng Y. Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget 2017;8:90215-24. [PMID: 29163822 DOI: 10.18632/oncotarget.21652] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
121 Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol 2021. [PMID: 34168333 DOI: 10.1038/s41571-021-00520-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Castellanos EH, Feld E, Estrada MV, Sanders ME, Massion PP, Johnson DB, Balko JM, Horn L. Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy. JCO Precis Oncol 2017;1:PO. [PMID: 32913978 DOI: 10.1200/PO.17.00049] [Reference Citation Analysis]
123 Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell. 2017;169:750-765.e17. [PMID: 28475900 DOI: 10.1016/j.cell.2017.04.014] [Cited by in Crossref: 495] [Cited by in F6Publishing: 487] [Article Influence: 99.0] [Reference Citation Analysis]
124 Chénard-poirier M, Smyth EC. Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer. Drugs 2019;79:1-10. [DOI: 10.1007/s40265-018-1032-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
125 Takada K, Okamoto T, Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Lung Cancer 2017;104:7-15. [PMID: 28213003 DOI: 10.1016/j.lungcan.2016.12.006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
126 Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother 2016;12:2777-89. [PMID: 27398650 DOI: 10.1080/21645515.2016.1199310] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
127 Polo V, Pasello G, Frega S, Favaretto A, Koussis H, Conte P, Bonanno L. Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. Oncotarget 2016;7:25050-63. [PMID: 26933818 DOI: 10.18632/oncotarget.7732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
128 Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer 2019;121:809-18. [PMID: 31607751 DOI: 10.1038/s41416-019-0599-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 19.0] [Reference Citation Analysis]
129 Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer J 2016;22:117-20. [PMID: 27111907 DOI: 10.1097/PPO.0000000000000176] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 5.6] [Reference Citation Analysis]
130 Satoh K, Kobayashi Y, Fujimaki K, Hayashi S, Ishida S, Sugiyama D, Sato T, Lim K, Miyamoto M, Kozuma S, Kadokura M, Wakita K, Hata M, Hirahara K, Amano M, Watanabe I, Okamoto A, Tuettenberg A, Jonuleit H, Tanemura A, Maruyama S, Agatsuma T, Wada T, Nishikawa H. Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells. Int Immunol 2021;33:435-46. [PMID: 34235533 DOI: 10.1093/intimm/dxab027] [Reference Citation Analysis]
131 Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, Wu Y, Zhu X, Chen X, Xie S, Yi X, Liang A, Zeng Y. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine (Baltimore) 2017;96:e6398. [PMID: 28403071 DOI: 10.1097/MD.0000000000006398] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
132 Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 2016;18:1357-66. [PMID: 27370400 DOI: 10.1093/neuonc/now132] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 13.8] [Reference Citation Analysis]
133 Cescon DW, Haibe-Kains B, Mak TW. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A 2015;112:2841-6. [PMID: 25730878 DOI: 10.1073/pnas.1424869112] [Cited by in Crossref: 90] [Cited by in F6Publishing: 86] [Article Influence: 12.9] [Reference Citation Analysis]
134 An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, Munshi NC, Qiu L, Tai Y, Anderson KC. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood 2016;128:1590-603. [DOI: 10.1182/blood-2016-03-707547] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 14.5] [Reference Citation Analysis]
135 Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol 2017;24:235-51. [PMID: 28777142 DOI: 10.1097/PAP.0000000000000162] [Cited by in Crossref: 213] [Cited by in F6Publishing: 125] [Article Influence: 53.3] [Reference Citation Analysis]
136 Niu X, Wang W, Liang T, Li S, Yang C, Xu X, Li L, Liu S. CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer. Cancer Sci 2021. [PMID: 34727389 DOI: 10.1111/cas.15190] [Reference Citation Analysis]
137 Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2020;6:375-84. [PMID: 31876895 DOI: 10.1001/jamaoncol.2019.5367] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 36.5] [Reference Citation Analysis]
138 Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer 2015;3:36. [PMID: 26288737 DOI: 10.1186/s40425-015-0078-9] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 15.9] [Reference Citation Analysis]
139 Thomas A, Giaccone G. Why has active immunotherapy not worked in lung cancer? Ann Oncol 2015;26:2213-20. [PMID: 26232492 DOI: 10.1093/annonc/mdv323] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
140 Day D, Monjazeb AM, Sharon E, Ivy SP, Rubin EH, Rosner GL, Butler MO. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. Clin Cancer Res 2017;23:4980-91. [PMID: 28864726 DOI: 10.1158/1078-0432.CCR-16-3064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
141 Hu X, Wu T, Qin X, Qi Y, Qiao Q, Yang C, Zhang Z. Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy. Adv Healthcare Mater 2019;8:1800837. [DOI: 10.1002/adhm.201800837] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
142 Amrein MA, Bührer ED, Amrein ML, Li Q, Rothschild S, Riether C, Jaggi R, Savic-Prince S, Bubendorf L, Gautschi O, Ochsenbein AF. Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study. Cancer Immunol Immunother 2021;70:405-15. [PMID: 32767058 DOI: 10.1007/s00262-020-02688-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Zeng Z, Pu K. Improving Cancer Immunotherapy by Cell Membrane‐Camouflaged Nanoparticles. Adv Funct Mater 2020;30:2004397. [DOI: 10.1002/adfm.202004397] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 20.5] [Reference Citation Analysis]
144 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015;3:399-411. [PMID: 25678581 DOI: 10.1158/2326-6066.cir-14-0215] [Cited by in Crossref: 242] [Cited by in F6Publishing: 171] [Article Influence: 34.6] [Reference Citation Analysis]
145 Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13:1156-1170. [PMID: 29777823 DOI: 10.1016/j.jtho.2018.04.039] [Cited by in Crossref: 97] [Cited by in F6Publishing: 104] [Article Influence: 24.3] [Reference Citation Analysis]
146 Bernier C, Soliman A, Gravel M, Dankner M, Savage P, Petrecca K, Park M, Siegel PM, Shore GC, Roulston A. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anticancer Drugs 2018;29:774-85. [PMID: 29878901 DOI: 10.1097/CAD.0000000000000653] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
147 Del Re M, Vivaldi C, Rofi E, Salani F, Crucitta S, Catanese S, Fontanelli L, Massa V, Cucchiara F, Fornaro L, Capuano A, Fogli S, Vasile E, Danesi R. Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Cancers (Basel) 2021;13:3738. [PMID: 34359638 DOI: 10.3390/cancers13153738] [Reference Citation Analysis]
148 Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019;18:197-218. [PMID: 30610226 DOI: 10.1038/s41573-018-0007-y] [Cited by in Crossref: 655] [Cited by in F6Publishing: 653] [Article Influence: 218.3] [Reference Citation Analysis]
149 Bockorny B, Pectasides E. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. Future Oncol. 2016;12:1833-1846. [PMID: 27166503 DOI: 10.2217/fon-2016-0103] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
150 Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681-700. [PMID: 26484443 DOI: 10.1038/nrgastro.2015.173] [Cited by in Crossref: 252] [Cited by in F6Publishing: 262] [Article Influence: 36.0] [Reference Citation Analysis]
151 Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, Rost S, Smith D, Dennis E, Tang SY, Damadzadeh B, Walker E, Hegde PS, Williams JA, Koeppen H, Boyd Z. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. Appl Immunohistochem Mol Morphol 2019;27:92-100. [PMID: 29346180 DOI: 10.1097/PAI.0000000000000594] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 35.0] [Reference Citation Analysis]
152 Martinez-Morilla S, McGuire J, Gaule P, Moore L, Acs B, Cougot D, Gown AM, Yaziji H, Wang WL, Cartun RW, Hornick JL, Sholl LM, Qiu J, Mino-Kenudson M, Yi ES, Beasley MB, Merrick DT, Ambaye AB, Zhang ZJ, Walker J, Rimm DL. Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. Lab Invest 2020;100:4-15. [PMID: 31409885 DOI: 10.1038/s41374-019-0295-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
153 Ren R, Koti M, Hamilton T, Graham CH, Nayak JG, Singh J, Drachenberg DE, Siemens DR. A primer on tumour immunology and prostate cancer immunotherapy. Can Urol Assoc J 2016;10:60-5. [PMID: 26977209 DOI: 10.5489/cuaj.3418] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
154 Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treat Rev 2018;66:104-13. [PMID: 29730461 DOI: 10.1016/j.ctrv.2018.04.004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
155 Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov 2017;7:264-76. [PMID: 28031159 DOI: 10.1158/2159-8290.CD-16-0828] [Cited by in Crossref: 402] [Cited by in F6Publishing: 278] [Article Influence: 67.0] [Reference Citation Analysis]
156 Martin AM, Nirschl CJ, Polanczyk MJ, Bell WR, Nirschl TR, Harris-Bookman S, Phallen J, Hicks J, Martinez D, Ogurtsova A, Xu H, Sullivan LM, Meeker AK, Raabe EH, Cohen KJ, Eberhart CG, Burger PC, Santi M, Taube JM, Pardoll DM, Drake CG, Lim M. PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget 2018;9:19177-91. [PMID: 29721192 DOI: 10.18632/oncotarget.24951] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
157 Curti BD, Urba WJ. Clinical deployment of antibodies for treatment of melanoma. Mol Immunol 2015;67:18-27. [PMID: 25746916 DOI: 10.1016/j.molimm.2015.01.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
158 Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34:2969-2979. [PMID: 27354481 DOI: 10.1200/jco.2016.66.9861] [Cited by in Crossref: 258] [Cited by in F6Publishing: 161] [Article Influence: 43.0] [Reference Citation Analysis]
159 Amin S, Baine M, Meza J, Alam M, Lin C. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. Clin Transl Radiat Oncol 2020;24:34-40. [PMID: 32613090 DOI: 10.1016/j.ctro.2020.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
160 Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. J Thorac Oncol 2018;13:521-32. [PMID: 29269008 DOI: 10.1016/j.jtho.2017.11.132] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 10.4] [Reference Citation Analysis]
161 An YS, Kim SH, Roh TH, Park SH, Kim TG, Kim JH. Correlation Between 18F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions. Front Oncol 2021;11:618705. [PMID: 34249674 DOI: 10.3389/fonc.2021.618705] [Reference Citation Analysis]
162 Bates AM, Lanzel EA, Qian F, Abbasi T, Vali S, Brogden KA. Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study. Oral Surg Oral Med Oral Pathol Oral Radiol 2017;124:157-64. [PMID: 28756882 DOI: 10.1016/j.oooo.2017.05.474] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
163 Stroh M, Green M, Millard BL, Apgar JF, Burke JM, Garner W, Lu H, Lyman SK, Desnoyers LR, Richardson J, Hannah A, Kavanaugh WM. Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072. Clin Pharmacol Ther 2021;109:383-93. [PMID: 32681519 DOI: 10.1002/cpt.1985] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
164 Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PTF, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Mol Ther 2018;26:2553-66. [PMID: 30217730 DOI: 10.1016/j.ymthe.2018.08.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
165 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 32.8] [Reference Citation Analysis]
166 Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. J Natl Cancer Inst 2020;112:562-73. [PMID: 32145020 DOI: 10.1093/jnci/djaa021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
167 Bence C, Hofman V, Chamorey E, Long-Mira E, Lassalle S, Albertini AF, Liolios I, Zahaf K, Picard A, Montaudié H, Lacour JP, Passeron T, Andea AA, Ilie M, Hofman P. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. J Eur Acad Dermatol Venereol 2020;34:984-94. [PMID: 31625630 DOI: 10.1111/jdv.16016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
168 Hirth M, Gandla J, Kuner R. A checkpoint to pain. Nat Neurosci 2017;20:897-9. [PMID: 28653690 DOI: 10.1038/nn.4586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
169 Pérez-Romero K, Rodríguez RM, Amedei A, Barceló-Coblijn G, Lopez DH. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy. Int J Mol Sci 2020;21:E5521. [PMID: 32752264 DOI: 10.3390/ijms21155521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Saraggi D, Galuppini F, Remo A, Urso EDL, Bacchin D, Salmaso R, Lanza C, Bao RQ, Fanelli GN, Guzzardo V, Luchini C, Scarpa M, Farinati F, Fassan M, Rugge M. PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. Histopathology 2017;71:470-4. [DOI: 10.1111/his.13254] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
171 Tan WCC, Nerurkar SN, Cai HY, Ng HHM, Wu D, Wee YTF, Lim JCT, Yeong J, Lim TKH. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun (Lond) 2020;40:135-53. [PMID: 32301585 DOI: 10.1002/cac2.12023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 26.5] [Reference Citation Analysis]
172 Chen D, Zhang X. Cellular immunity augmentation in mainstream oncologic therapy. Cancer Biol Med 2017;14:121-8. [PMID: 28607803 DOI: 10.20892/j.issn.2095-3941.2017.0022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
173 Magalhães H, Fontes-Sousa M, Machado M. Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies. Can J Gastroenterol Hepatol 2018;2018:2732408. [PMID: 30027089 DOI: 10.1155/2018/2732408] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
174 Becht E, Giraldo NA, Beuselinck B, Job S, Marisa L, Vano Y, Oudard S, Zucman-Rossi J, Laurent-Puig P, Sautès-Fridman C, de Reyniès A, Fridman WH. Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). Oncoimmunology 2015;4:e1049804. [PMID: 26587318 DOI: 10.1080/2162402X.2015.1049804] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 4.1] [Reference Citation Analysis]
175 Mao D, Zhou Z, Song S, Li D, He Y, Wei Z, Zhang C. Identification of Stemness Characteristics Associated With the Immune Microenvironment and Prognosis in Gastric Cancer. Front Oncol 2021;11:626961. [PMID: 33747944 DOI: 10.3389/fonc.2021.626961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 Nakamura K, Ashida A, Kiniwa Y, Okuyama R. Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. Arch Dermatol Res 2021. [PMID: 34842960 DOI: 10.1007/s00403-021-02305-z] [Reference Citation Analysis]
177 Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018;6:4. [PMID: 29368638 DOI: 10.1186/s40425-018-0314-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 18.8] [Reference Citation Analysis]
178 Domblides C, Antoine M, Hamard C, Rabbe N, Rodenas A, Vieira T, Crequit P, Cadranel J, Lavolé A, Wislez M. Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates. AIDS 2018;32:461-8. [PMID: 29194117 DOI: 10.1097/QAD.0000000000001713] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
179 Skevaki C, Van den Berg J, Jones N, Garssen J, Vuillermin P, Levin M, Landay A, Renz H, Calder PC, Thornton CA. Immune biomarkers in the spectrum of childhood noncommunicable diseases. J Allergy Clin Immunol 2016;137:1302-16. [PMID: 27155027 DOI: 10.1016/j.jaci.2016.03.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
180 Rivera-Colon G, Chen H, Molberg K, Niu S, Strickland AL, Castrillon DH, Carrick K, Gwin K, Lea J, Zheng W, Lucas E. PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes. Am J Surg Pathol 2021;45:742-52. [PMID: 33298732 DOI: 10.1097/PAS.0000000000001633] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 2016;7:59976-86. [PMID: 27527850 DOI: 10.18632/oncotarget.11045] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
182 Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015;125:3393-400. [PMID: 25833961 DOI: 10.1182/blood-2015-02-567453] [Cited by in Crossref: 157] [Cited by in F6Publishing: 153] [Article Influence: 22.4] [Reference Citation Analysis]
183 Fucà G, Spagnoletti A, Ambrosini M, de Braud F, Di Nicola M. Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy. ESMO Open 2021;6:100046. [PMID: 33508733 DOI: 10.1016/j.esmoop.2020.100046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Suzuki S, Ishida T, Yoshikawa K, Ueda R. Current status of immunotherapy. Jpn J Clin Oncol 2016;46:191-203. [PMID: 26819277 DOI: 10.1093/jjco/hyv201] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
185 Zhang X, Wang J, Shi J, Jia X, Dang S, Wang W. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma. JAMA Netw Open 2021;4:e214846. [PMID: 33825837 DOI: 10.1001/jamanetworkopen.2021.4846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Meng X, Gao Y, Yang L, Jing H, Teng F, Huang Z, Xing L. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis. Clin Lung Cancer 2019;20:48-58. [PMID: 30341017 DOI: 10.1016/j.cllc.2018.09.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
187 Xu X, Xie K, Li B, Xu L, Huang L, Feng Y, Pi C, Zhang J, Huang T, Jiang M, Gu H, Fang J. Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression. Int Immunopharmacol 2021;101:108199. [PMID: 34673297 DOI: 10.1016/j.intimp.2021.108199] [Reference Citation Analysis]
188 Penaloza-MacMaster P. CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. Immunology 2017;151:146-53. [PMID: 28375543 DOI: 10.1111/imm.12739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
189 Ji S, Lee J, Lee ES, Kim DH, Sin JI. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Hum Vaccin Immunother 2021;17:1910-22. [PMID: 33522416 DOI: 10.1080/21645515.2020.1866951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
190 Watanabe T, Okuda K, Murase T, Moriyama S, Haneda H, Kawano O, Yokota K, Sakane T, Oda R, Inagaki H, Nakanishi R. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. Oncotarget 2018;9:20769-80. [PMID: 29755688 DOI: 10.18632/oncotarget.25100] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
191 Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, Schlom J, Hodge JW. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget 2016;7:16130-45. [PMID: 26910920 DOI: 10.18632/oncotarget.7470] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 19.0] [Reference Citation Analysis]
192 Su Z, Zhou L, Xue J, Lu Y. Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. Chin J Cancer Res 2020;32:448-66. [PMID: 32963458 DOI: 10.21147/j.issn.1000-9604.2020.04.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 Jalili-Nik M, Soltani A, Mashkani B, Rafatpanah H, Hashemy SI. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. Int Immunopharmacol 2021;98:107870. [PMID: 34153661 DOI: 10.1016/j.intimp.2021.107870] [Reference Citation Analysis]
194 Pistamaltzian NF, Georgoulias V, Kotsakis A. The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. Expert Review of Respiratory Medicine 2019;13:435-47. [DOI: 10.1080/17476348.2019.1593828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
195 Hu G, Tu W, Yang L, Peng G, Yang L. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. Cancer Lett 2020;473:148-55. [PMID: 31911080 DOI: 10.1016/j.canlet.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
196 Wang H, Shan Q, Guo J, Han X, Zhao C, Li H, Wang Z. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab. Lung Cancer 2021;151:76-83. [PMID: 33246647 DOI: 10.1016/j.lungcan.2020.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
197 Liu XS, Mardis ER. Applications of Immunogenomics to Cancer. Cell 2017;168:600-12. [PMID: 28187283 DOI: 10.1016/j.cell.2017.01.014] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 23.6] [Reference Citation Analysis]
198 Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL Jr. Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. Oncoimmunology 2016;5:e1240857. [PMID: 28123876 DOI: 10.1080/2162402X.2016.1240857] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 6.2] [Reference Citation Analysis]
199 Moroz A, Lee CY, Wang YH, Hsiao JC, Sevillano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ. A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4. Bioconjug Chem 2018;29:3476-82. [PMID: 30227708 DOI: 10.1021/acs.bioconjchem.8b00632] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
200 Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 2016;6:30093. [PMID: 27456063 DOI: 10.1038/srep30093] [Cited by in Crossref: 129] [Cited by in F6Publishing: 129] [Article Influence: 21.5] [Reference Citation Analysis]
201 Wang S, Guan G, Zou C, Guo Q, Cheng W, Shen S, Dong F, Wu A, Li G, Zhu C. Genome profiling of mismatch repair genes in eight types of tumors. Cell Cycle 2021;20:1091-106. [PMID: 33966609 DOI: 10.1080/15384101.2021.1922160] [Reference Citation Analysis]
202 Pai SI, Cesano A, Marincola FM. The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. Cancer Treat Res 2020;180:173-95. [PMID: 32215870 DOI: 10.1007/978-3-030-38862-1_6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
203 Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra-Cuentas ER, Wistuba II, Soucheray M, Thai T, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res 2016;76:999-1008. [PMID: 26833127 DOI: 10.1158/0008-5472.CAN-15-1439] [Cited by in Crossref: 241] [Cited by in F6Publishing: 154] [Article Influence: 40.2] [Reference Citation Analysis]
204 Anari F, Ramamurthy C, Zibelman M. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. Future Oncol 2018;14:1409-21. [PMID: 29848096 DOI: 10.2217/fon-2017-0585] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
205 Nam J, Son S, Park KS, Zou W, Shea LD, Moon JJ. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater 2019;4:398-414. [DOI: 10.1038/s41578-019-0108-1] [Cited by in Crossref: 261] [Cited by in F6Publishing: 147] [Article Influence: 87.0] [Reference Citation Analysis]
206 Zhang J, Dang F, Ren J, Wei W. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends Biochem Sci 2018;43:1014-32. [PMID: 30287140 DOI: 10.1016/j.tibs.2018.09.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
207 Sandler JE, Kaumaya M, Halmos B. Biomarker use in lung cancer management: expanding horizons. Biomark Med 2018;12:315-20. [PMID: 29569465 DOI: 10.2217/bmm-2018-0028] [Reference Citation Analysis]
208 Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. J Thorac Oncol 2019;14:1807-17. [PMID: 31238177 DOI: 10.1016/j.jtho.2019.06.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
209 Furuya N, Nishino M, Wakuda K, Ikeda S, Sato T, Ushio R, Tanzawa S, Sata M, Ito K. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody. Thorac Cancer 2021;12:613-8. [PMID: 33448648 DOI: 10.1111/1759-7714.13824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
210 Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015;10:974-84. [PMID: 26134219 DOI: 10.1097/JTO.0000000000000551] [Cited by in Crossref: 65] [Cited by in F6Publishing: 37] [Article Influence: 10.8] [Reference Citation Analysis]
211 Akabane H, Sullivan RJ. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. Am J Clin Dermatol 2016;17:1-10. [DOI: 10.1007/s40257-015-0159-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
212 Tomioka N, Azuma M, Ikarashi M, Yamamoto M, Sato M, Watanabe K, Yamashiro K, Takahashi M. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer 2018;25:34-42. [DOI: 10.1007/s12282-017-0781-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
213 Fukushima Y, Someya M, Nakata K, Hori M, Kitagawa M, Hasegawa T, Tsuchiya T, Gocho T, Ikeda H, Hirohashi Y, Torigoe T, Sugita S, Hasegawa T, Himi T, Sakata KI. Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma. Radiother Oncol 2018;129:409-14. [PMID: 30249348 DOI: 10.1016/j.radonc.2018.08.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
214 Lote H, Cafferkey C, Chau I. PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treat Rev. 2015;41:893-903. [PMID: 26412280 DOI: 10.1016/j.ctrv.2015.09.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
215 Chen Q, Yin H, Pu N, Zhang J, Zhao G, Wenhui L, Wu W. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth. Cancer Sci 2021. [PMID: 34402138 DOI: 10.1111/cas.15110] [Reference Citation Analysis]
216 Bidnur S, Savdie R, Black PC. Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer 2016;2:15-25. [PMID: 27376121 DOI: 10.3233/BLC-150026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
217 Trono P, Sistigu A, Palermo B, Ciliberto G, Nisticò P. Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerg Top Life Sci 2017;1:471-86. [PMID: 33525801 DOI: 10.1042/ETLS20170068] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
218 Karachi A, Yang C, Dastmalchi F, Sayour EJ, Huang J, Azari H, Long Y, Flores C, Mitchell DA, Rahman M. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol 2019;21:730-41. [PMID: 30668768 DOI: 10.1093/neuonc/noz015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
219 Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol. 2016;27:214-224. [PMID: 26578728 DOI: 10.1093/annonc/mdv550] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 9.1] [Reference Citation Analysis]
220 Zhou Z, Zhang J, Xu C, Yang J, Zhang Y, Liu M, Shi X, Li X, Zhan H, Chen W, McNally LR, Fung KM, Luo W, Houchen CW, He Y, Zhang C, Li M. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. EBioMedicine 2021;65:103271. [PMID: 33714027 DOI: 10.1016/j.ebiom.2021.103271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
221 Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66:794-801. [PMID: 26801886 DOI: 10.1136/gutjnl-2015-310839] [Cited by in Crossref: 206] [Cited by in F6Publishing: 217] [Article Influence: 34.3] [Reference Citation Analysis]
222 Gil M, Kim KE. Interleukin-18 Is a Prognostic Biomarker Correlated with CD8+ T Cell and Natural Killer Cell Infiltration in Skin Cutaneous Melanoma. J Clin Med 2019;8:E1993. [PMID: 31731729 DOI: 10.3390/jcm8111993] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
223 Soo RA, Kim HR, Asuncion BR, Fazreen Z, Omar MFM, Herrera MC, Yun Lim JS, Sia G, Soong R, Cho B. Significance of immune checkpoint proteins in EGFR -mutant non-small cell lung cancer. Lung Cancer 2017;105:17-22. [DOI: 10.1016/j.lungcan.2017.01.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
224 Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL Jr, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell 2020;38:500-515.e3. [PMID: 32916126 DOI: 10.1016/j.ccell.2020.08.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
225 Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A, Lambris JD. Complementing the Cancer-Immunity Cycle. Front Immunol 2019;10:774. [PMID: 31031765 DOI: 10.3389/fimmu.2019.00774] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
226 Hossain DMS, Javaid S, Cai M, Zhang C, Sawant A, Hinton M, Sathe M, Grein J, Blumenschein W, Pinheiro EM, Chackerian A. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. J Clin Invest 2018;128:644-54. [PMID: 29337311 DOI: 10.1172/JCI94586] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 12.8] [Reference Citation Analysis]
227 Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ, Sato T. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy 2017;9:1323-30. [PMID: 29185395 DOI: 10.2217/imt-2017-0066] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
228 Zhu Y, Hu H, Ding D, Li S, Liao M, Shi Y, Huang J. First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis. Cost Eff Resour Alloc 2021;19:77. [PMID: 34863203 DOI: 10.1186/s12962-021-00329-w] [Reference Citation Analysis]
229 Nambiar DK, Aguilera T, Cao H, Kwok S, Kong C, Bloomstein J, Wang Z, Rangan VS, Jiang D, von Eyben R, Liang R, Agarwal S, Colevas AD, Korman A, Allen CT, Uppaluri R, Koong AC, Giaccia A, Le QT. Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. J Clin Invest 2019;129:5553-67. [PMID: 31710313 DOI: 10.1172/JCI129025] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
230 Michalarea V, Fontana E, Garces AI, Williams A, Smyth EC, Picchia S, Rao S, Chau I, Cunningham D, Bali MA. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. Curr Probl Cancer 2019;43:487-94. [PMID: 30827742 DOI: 10.1016/j.currproblcancer.2019.01.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
231 Outh-gauer S, Le Tourneau C, Broudin C, Scotte F, Roussel H, Hans S, Mandavit M, Tartour E, Badoual C. Actualités sur l’immunothérapie en pathologie des voies aérodigestives supérieures. Annales de Pathologie 2017;37:79-89. [DOI: 10.1016/j.annpat.2016.12.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
232 Gong N, Zhang Y, Zhang Z, Li X, Liang X. Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. Adv Funct Mater 2019;29:1806087. [DOI: 10.1002/adfm.201806087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
233 Wang Y, Rui M, Yang L, Wang X, Shang Y, Ma A, Li H. Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US. Front Public Health 2021;9:650392. [PMID: 33889559 DOI: 10.3389/fpubh.2021.650392] [Reference Citation Analysis]
234 Fontugne J, Augustin J, Pujals A, Compagnon P, Rousseau B, Luciani A, Tournigand C, Cherqui D, Azoulay D, Pawlotsky JM, Calderaro J. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 2017;8:24644-51. [PMID: 28445951 DOI: 10.18632/oncotarget.15602] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 19.5] [Reference Citation Analysis]
235 Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clin Transl Med 2018;7:32. [PMID: 30294755 DOI: 10.1186/s40169-018-0210-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
236 Li Y, Lu S, Wang S, Peng X, Lang J. Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses. J Transl Med 2021;19:222. [PMID: 34030694 DOI: 10.1186/s12967-021-02894-3] [Reference Citation Analysis]
237 Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 2018;128:805-15. [PMID: 29337305 DOI: 10.1172/JCI96113] [Cited by in Crossref: 207] [Cited by in F6Publishing: 147] [Article Influence: 51.8] [Reference Citation Analysis]
238 Hou J, Xing L, Yuan Y. A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung. Clin Exp Med 2018;18:555-62. [DOI: 10.1007/s10238-018-0517-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
239 Cubas R, Khan Z, Gong Q, Moskalenko M, Xiong H, Ou Q, Pai C, Rodriguez R, Cheung J, Chan AC. Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy. J Immunother Cancer 2020;8:e001439. [PMID: 33127657 DOI: 10.1136/jitc-2020-001439] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
240 Zaemes J, Alzeer A, Villa K, Atkins M. A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor. Immunotherapy 2020;12:861-7. [PMID: 32640856 DOI: 10.2217/imt-2020-0139] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
241 Hu FF, Liu CJ, Liu LL, Zhang Q, Guo AY. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Brief Bioinform 2021;22:bbaa176. [PMID: 32814346 DOI: 10.1093/bib/bbaa176] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
242 Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun 2017;8:14754. [PMID: 28345650 DOI: 10.1038/ncomms14754] [Cited by in Crossref: 136] [Cited by in F6Publishing: 144] [Article Influence: 27.2] [Reference Citation Analysis]
243 Yeo KP, Angeli V. Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity. Front Immunol 2017;8:83. [PMID: 28220121 DOI: 10.3389/fimmu.2017.00083] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
244 Tsiara A, Liontos M, Kaparelou M, Zakopoulou R, Bamias A, Dimopoulos MA. Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Ann Transl Med 2018;6:144. [PMID: 29862233 DOI: 10.21037/atm.2018.02.07] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
245 Li Q, Quan L, Lyu J, He Z, Wang X, Meng J, Zhao Z, Zhu L, Liu X, Li H. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget 2016;7:64967-76. [PMID: 27533458 DOI: 10.18632/oncotarget.11274] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
246 Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, Fox BA, Ascierto PA. PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. Oncoimmunology 2018;7:e1405206. [PMID: 30524879 DOI: 10.1080/2162402X.2017.1405206] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
247 Black M, Barsoum IB, Truesdell P, Cotechini T, Macdonald-Goodfellow SK, Petroff M, Siemens DR, Koti M, Craig AW, Graham CH. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget 2016;7:10557-67. [PMID: 26859684 DOI: 10.18632/oncotarget.7235] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 15.3] [Reference Citation Analysis]
248 Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol 2022;15:6. [PMID: 35033167 DOI: 10.1186/s13045-021-01182-3] [Reference Citation Analysis]
249 Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology 2017;6:e1253654. [PMID: 28344865 DOI: 10.1080/2162402X.2016.1253654] [Cited by in Crossref: 80] [Cited by in F6Publishing: 57] [Article Influence: 16.0] [Reference Citation Analysis]
250 Dhillon S, Syed YY. Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC. Target Oncol 2019;14:759-68. [PMID: 31728860 DOI: 10.1007/s11523-019-00686-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
251 Deng B, Park JH, Ren L, Yew PY, Kiyotani K, Antic T, O'Connor K, O'Donnell PH, Nakamura Y. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Cancer Rep (Hoboken) 2018;1:e1002. [PMID: 32729250 DOI: 10.1002/cnr2.1002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
252 Pawłowska A, Kwiatkowska A, Suszczyk D, Chudzik A, Tarkowski R, Barczyński B, Kotarski J, Wertel I. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients. Int J Mol Sci 2021;22:11563. [PMID: 34768993 DOI: 10.3390/ijms222111563] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clin Cancer Res 2015;21:3052-60. [PMID: 25788491 DOI: 10.1158/1078-0432.CCR-14-3073] [Cited by in Crossref: 134] [Cited by in F6Publishing: 85] [Article Influence: 19.1] [Reference Citation Analysis]
254 Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, Cui Q, Han E, Tobin J, Bird R, Cross D, Hernandez A, Gould C, Birch S, Gandhi MK. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 2018;131:1809-19. [PMID: 29449276 DOI: 10.1182/blood-2017-07-796342] [Cited by in Crossref: 125] [Cited by in F6Publishing: 124] [Article Influence: 31.3] [Reference Citation Analysis]
255 Mao S, Li Y, Lu Z, Che Y, Huang J, Lei Y, Wang Y, Wang X, Liu C, Zheng S, Li N, Li J, Sun N, He J. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cell Oncol (Dordr) 2020;43:681-94. [PMID: 32462608 DOI: 10.1007/s13402-020-00515-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
256 Mills A, Zadeh S, Sloan E, Chinn Z, Modesitt SC, Ring KL. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol 2018;31:1282-90. [PMID: 29559741 DOI: 10.1038/s41379-018-0039-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
257 Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 2015;6:7458. [PMID: 26109379 DOI: 10.1038/ncomms8458] [Cited by in Crossref: 225] [Cited by in F6Publishing: 220] [Article Influence: 32.1] [Reference Citation Analysis]
258 Zhang X, Cheng C, Hou J, Qi X, Wang X, Han P, Yang X. Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells. Cell Mol Immunol 2019;16:392-400. [PMID: 29568117 DOI: 10.1038/s41423-018-0021-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
259 Pu X, Wu L, Su D, Mao W, Fang B. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer 2018;18:1082. [PMID: 30409126 DOI: 10.1186/s12885-018-4990-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
260 Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, Wild PJ. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget 2018;9:10284-93. [PMID: 29535806 DOI: 10.18632/oncotarget.22888] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
261 Juliá EP, Mandó P, Rizzo MM, Cueto GR, Tsou F, Luca R, Pupareli C, Bravo AI, Astorino W, Mordoh J, Martín C, Levy EM. Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. Cancer Immunol Immunother 2019;68:1585-96. [DOI: 10.1007/s00262-019-02391-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
262 Gao L, Yang X, Yi C, Zhu H. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. Front Pharmacol 2019;10:1173. [PMID: 31680957 DOI: 10.3389/fphar.2019.01173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
263 Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 2020;11:2135. [PMID: 32358509 DOI: 10.1038/s41467-020-15959-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
264 Qu S, Jiao Z, Lu G, Yao B, Wang T, Rong W, Xu J, Fan T, Sun X, Yang R, Wang J, Yao Y, Xu G, Yan X, Wang T, Liang H, Zen K. PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biol 2021;22:104. [PMID: 33849634 DOI: 10.1186/s13059-021-02331-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med 2015;12:74-8. [PMID: 26175922 DOI: 10.7497/j.issn.2095-3941.2015.0022] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
266 Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for Immunotherapy: Current Developments and Challenges. Am Soc Clin Oncol Educ Book 2016;35:e493-503. [PMID: 27249758 DOI: 10.1200/EDBK_160766] [Cited by in Crossref: 21] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
267 Chiang AC, Sequist LVD, Gilbert J, Conkling P, Thompson D, Marcoux JP, Gettinger S, Kowanetz M, Molinero L, O’hear C, Fassò M, Lam S, Gordon MS. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clinical Lung Cancer 2020;21:455-463.e4. [DOI: 10.1016/j.cllc.2020.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
268 Hellmann MD, Friedman CF, Wolchok JD. Combinatorial Cancer Immunotherapies. Adv Immunol 2016;130:251-77. [PMID: 26923003 DOI: 10.1016/bs.ai.2015.12.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
269 Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J, Parra ER, Rebelatto MC, Rimm DL, Rodriguez-Canales J, Schalper KA, Stack EC, Ferreira CS, Korski K, Lako A, Rodig SJ, Schenck E, Steele KE, Surace MJ, Tetzlaff MT, von Loga K, Wistuba II, Bifulco CB; Society for Immunotherapy of Cancer (SITC) Pathology Task Force. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. J Immunother Cancer 2020;8:e000155. [PMID: 32414858 DOI: 10.1136/jitc-2019-000155] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
270 Bayraktar R, Van Roosbroeck K. miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer Metastasis Rev 2018;37:33-44. [PMID: 29282605 DOI: 10.1007/s10555-017-9724-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 21.0] [Reference Citation Analysis]
271 Zhu SK, Xu T, Wang R. Prospects and challenges of immunotherapy for pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2019; 27(1): 6-12 [DOI: 10.11569/wcjd.v27.i1.6] [Reference Citation Analysis]
272 Platten M, Bunse L, Wick W, Bunse T. Concepts in glioma immunotherapy. Cancer Immunol Immunother 2016;65:1269-75. [DOI: 10.1007/s00262-016-1874-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
273 Wu AM, Pandit-Taskar N. ImmunoPET: harnessing antibodies for imaging immune cells. Mol Imaging Biol 2021. [PMID: 34550529 DOI: 10.1007/s11307-021-01652-7] [Reference Citation Analysis]
274 Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clin Cancer Res 2017;23:370-8. [PMID: 27440266 DOI: 10.1158/1078-0432.CCR-16-0150] [Cited by in Crossref: 87] [Cited by in F6Publishing: 66] [Article Influence: 14.5] [Reference Citation Analysis]
275 Koopmans I, Hendriks D, Samplonius DF, van Ginkel RJ, Heskamp S, Wierstra PJ, Bremer E, Helfrich W. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. Oncoimmunology 2018;7:e1466016. [PMID: 30221065 DOI: 10.1080/2162402X.2018.1466016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
276 Paulsen EE, Kilvaer TK, Khanehkenari MR, Al-Saad S, Hald SM, Andersen S, Richardsen E, Ness N, Busund LT, Bremnes RM, Donnem T. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach. Clin Lung Cancer 2017;18:220-233.e8. [PMID: 27816392 DOI: 10.1016/j.cllc.2016.09.009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
277 Mylvaganam G, Yanez AG, Maus M, Walker BD. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Front Immunol 2019;10:2109. [PMID: 31552045 DOI: 10.3389/fimmu.2019.02109] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
278 Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer 2018;101:114-22. [PMID: 30053670 DOI: 10.1016/j.ejca.2018.06.033] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
279 Guo Y, Jin Y, Wang B, Liu B. Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization. Int J Mol Sci 2021;22:4766. [PMID: 33946261 DOI: 10.3390/ijms22094766] [Reference Citation Analysis]
280 Zhou Y, Zong H, Han L, Xie Y, Jiang H, Gilly J, Zhang B, Lu H, Chen J, Sun R, Pan Z, Zhu J. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer. J Exp Clin Cancer Res 2020;39:87. [PMID: 32398042 DOI: 10.1186/s13046-020-01564-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
281 Mantia CM, Buchbinder EI. Immunotherapy Toxicity. Hematol Oncol Clin North Am 2019;33:275-90. [PMID: 30833000 DOI: 10.1016/j.hoc.2018.12.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
282 Zhang W, Pang Q, Zhang X, Yan C, Wang Q, Yang J, Yu S, Liu X, Pan Y, Yuan Z, Wang P, Xiao Z. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. Cancer Sci 2017;108:590-7. [PMID: 28192623 DOI: 10.1111/cas.13197] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
283 Yeong J, Lim JCT, Lee B, Li H, Chia N, Ong CCH, Lye WK, Putti TC, Dent R, Lim E, Thike AA, Tan PH, Iqbal J. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. Front Immunol 2018;9:1209. [PMID: 29899747 DOI: 10.3389/fimmu.2018.01209] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 12.5] [Reference Citation Analysis]
284 Klepsch V, Hermann-Kleiter N, Baier G. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. Immunol Lett 2016;178:31-6. [PMID: 26992368 DOI: 10.1016/j.imlet.2016.03.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
285 Zeidan AM, Stahl M, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion on Emerging Drugs 2016;21:283-300. [DOI: 10.1080/14728214.2016.1220534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
286 Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. Target Oncol 2017;12:125-38. [PMID: 27995439 DOI: 10.1007/s11523-016-0471-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
287 Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27:1492-1504. [PMID: 27207108 DOI: 10.1093/annonc/mdw217] [Cited by in Crossref: 219] [Cited by in F6Publishing: 211] [Article Influence: 36.5] [Reference Citation Analysis]
288 Cho J, Kim K, Kim HC, Lee WY, Kang WK, Park YS, Ha SY. The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. Pathology - Research and Practice 2019;215:171-6. [DOI: 10.1016/j.prp.2018.10.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
289 Singhal S, Stadanlick J, Annunziata MJ, Rao AS, Bhojnagarwala PS, O'Brien S, Moon EK, Cantu E, Danet-Desnoyers G, Ra HJ, Litzky L, Akimova T, Beier UH, Hancock WW, Albelda SM, Eruslanov EB. Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med 2019;11:eaat1500. [PMID: 30760579 DOI: 10.1126/scitranslmed.aat1500] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 31.5] [Reference Citation Analysis]
290 Guennoun A, Sidahmed H, Maccalli C, Seliger B, Marincola FM, Bedognetti D. Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Rev Clin Immunol 2016;12:879-93. [PMID: 27070898 DOI: 10.1080/1744666X.2016.1176529] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
291 Oya Y, Yoshida T, Kuroda H, Mikubo M, Kondo C, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget 2017;8:103117-28. [PMID: 29262550 DOI: 10.18632/oncotarget.21602] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
292 Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res 2019;25:4592-602. [PMID: 30824587 DOI: 10.1158/1078-0432.CCR-18-1538] [Cited by in Crossref: 141] [Cited by in F6Publishing: 99] [Article Influence: 47.0] [Reference Citation Analysis]
293 Hiniker SM, Maecker HT, Knox SJ. Predictors of clinical response to immunotherapy with or without radiotherapy. J Radiat Oncol. 2015;4:339-345. [PMID: 26709361 DOI: 10.1007/s13566-015-0219-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
294 Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Yamashita YI, Yoshida N, Chikamoto A, Baba H. The microbiome and hepatobiliary-pancreatic cancers.Cancer Lett. 2017;402:9-15. [PMID: 28527946 DOI: 10.1016/j.canlet.2017.05.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 11.4] [Reference Citation Analysis]
295 Cheah CY, Fowler NH, Neelapu SS. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol 2015;27:384-91. [PMID: 26248256 DOI: 10.1097/CCO.0000000000000212] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
296 Wahjudi LW, Bernhardt S, Abnaof K, Horak P, Kreutzfeldt S, Heining C, Borgoni S, Becki C, Berg D, Richter D, Hutter B, Uhrig S, Pfütze K, Leichsenring J, Glimm H, Brors B, von Kalle C, Stenzinger A, Korf U, Fröhling S, Wiemann S. Integrating proteomics into precision oncology. Int J Cancer 2021;148:1438-51. [PMID: 32949162 DOI: 10.1002/ijc.33301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
297 Sun X, Yan X, Zhuo W, Gu J, Zuo K, Liu W, Liang L, Gan Y, He G, Wan H, Gou X, Shi H, Hu J. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. Int J Mol Sci 2018;19:E1984. [PMID: 29986511 DOI: 10.3390/ijms19071984] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
298 Iga N, Otsuka A, Yamamoto Y, Nakashima C, Honda T, Kitoh A, Nakajima S, Egawa G, Nomura T, Dainichi T, Matsushita S, Tanizaki H, Yamamoto Y, Funakoshi T, Fujisawa Y, Fujimura T, Hata H, Ishida Y, Kabashima K. Accumulation of exhausted CD8+ T cells in extramammary Paget's disease. PLoS One 2019;14:e0211135. [PMID: 30682105 DOI: 10.1371/journal.pone.0211135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
299 Zhao C, Rajan A. Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk? Mediastinum 2019;3:35. [PMID: 31608320 DOI: 10.21037/med.2019.08.02] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
300 Haykal MM, Nahmias C, Varon C, Martin OCB. Organotypic Modeling of the Tumor Landscape. Front Cell Dev Biol 2020;8:606039. [PMID: 33330508 DOI: 10.3389/fcell.2020.606039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
301 Tang C, Chang JY. PD-L1 expression in lung cancer. J Thorac Dis 2016;8:3053-5. [PMID: 28066581 DOI: 10.21037/jtd.2016.11.38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
302 Hecht M, Gostian AO, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann MG, Klautke G, Laban S, Brunner T, Hinke A, Becker I, Frey B, Semrau S, Geppert CI, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Fietkau R. Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. J Immunother Cancer 2020;8:e001378. [PMID: 33023982 DOI: 10.1136/jitc-2020-001378] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
303 Asmar R, Yang J, Carvajal RD. Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag 2016;12:313-25. [PMID: 27013881 DOI: 10.2147/TCRM.S78039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
304 Goding SR, Wilson KA, Rosinsky C, Antony PA. PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4+ T Cell Adoptive Immunotherapy. J Immunol 2018;200:3304-11. [PMID: 29602773 DOI: 10.4049/jimmunol.1701617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
305 Yao Y, Liang H, Fang X, Zhang S, Xing Z, Shi L, Kuang C, Seliger B, Yang Q. What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past. J Exp Clin Cancer Res 2021;40:60. [PMID: 33557876 DOI: 10.1186/s13046-021-01847-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
306 Marabelle A, Gray J. Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy: Tumor- and Immune-Targeted Monoclonal Antibodies. Pediatr Blood Cancer 2015;62:1317-25. [DOI: 10.1002/pbc.25508] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
307 Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015;15:45-56. [PMID: 25534622 DOI: 10.1038/nri3790] [Cited by in Crossref: 339] [Cited by in F6Publishing: 320] [Article Influence: 48.4] [Reference Citation Analysis]
308 Lacour M, Hiltbrunner S, Lee SY, Soltermann A, Rushing EJ, Soldini D, Weder W, Curioni-Fontecedro A. Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence. Clin Lung Cancer 2019;20:391-6. [PMID: 31262689 DOI: 10.1016/j.cllc.2019.05.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
309 Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B. Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. J Transl Med 2018;16:328. [PMID: 30477533 DOI: 10.1186/s12967-018-1704-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
310 Jayaraj P, Sen S. Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance. Indian J Ophthalmol 2019;67:1983-7. [PMID: 31755433 DOI: 10.4103/ijo.IJO_2056_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
311 Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol. 2017;50:41-48. [PMID: 27922697 DOI: 10.3892/ijo.2016.3785] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
312 Yoon HK, Kim TH, Park S, Jung H, Quan X, Park SJ, Han J, Lee A. Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer. Pathology - Research and Practice 2018;214:1626-31. [DOI: 10.1016/j.prp.2018.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
313 Ye L, Ma S, Robinson BW, Creaney J. Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicine. Expert Rev Respir Med 2019;13:181-92. [PMID: 30596292 DOI: 10.1080/17476348.2019.1563488] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
314 Geraci E, Chablani L. Immunotherapy as a second-line or later treatment modality for advanced non-small cell lung cancer: A review of safety and efficacy. Crit Rev Oncol Hematol 2020;152:103009. [PMID: 32526609 DOI: 10.1016/j.critrevonc.2020.103009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
315 Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11. [PMID: 25901283 DOI: 10.1186/s40425-015-0057-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 174] [Article Influence: 26.3] [Reference Citation Analysis]
316 Horton BL, Morgan DM, Momin N, Zagorulya M, Torres-Mejia E, Bhandarkar V, Wittrup KD, Love JC, Spranger S. Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Sci Immunol 2021;6:eabi8800. [PMID: 34714687 DOI: 10.1126/sciimmunol.abi8800] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Liu S, Kong P, Wang X, Yang L, Jiang C, He W, Quan Q, Huang J, Xie Q, Xia X, Zhang B, Xia L. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer. Oncol Lett 2019;17:2335-43. [PMID: 30675299 DOI: 10.3892/ol.2018.9826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
318 Cha YJ, Kim HR, Lee CY, Cho BC, Shim HS. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer 2016;97:73-80. [DOI: 10.1016/j.lungcan.2016.05.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 13.5] [Reference Citation Analysis]
319 Russo E, Santoni A, Bernardini G. Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer. J Leukoc Biol 2020;108:673-85. [PMID: 32745326 DOI: 10.1002/JLB.5MR0320-205R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
320 Kaesler S, Wölbing F, Kempf WE, Skabytska Y, Köberle M, Volz T, Sinnberg T, Amaral T, Möckel S, Yazdi A, Metzler G, Schaller M, Hartmann K, Weide B, Garbe C, Rammensee HG, Röcken M, Biedermann T. Targeting tumor-resident mast cells for effective anti-melanoma immune responses. JCI Insight 2019;4:125057. [PMID: 31578309 DOI: 10.1172/jci.insight.125057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
321 Jiang H, Ni H, Zhang P, Guo X, Wu M, Shen H, Wang J, Wu W, Wu Z, Ding J, Tang R, Zhou S, Chen B, Yu M, Jing H, Liu J. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. Oncoimmunology 2021;10:1943180. [PMID: 34239776 DOI: 10.1080/2162402X.2021.1943180] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
322 Manni S, Carrino M, Semenzato G, Piazza F. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. Int J Mol Sci 2018;19:E1512. [PMID: 29783691 DOI: 10.3390/ijms19051512] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
323 Li QX, Feuer G, Ouyang X, An X. Experimental animal modeling for immuno-oncology. Pharmacol Ther 2017;173:34-46. [PMID: 28167217 DOI: 10.1016/j.pharmthera.2017.02.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
324 He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol 2017;12:814-23. [PMID: 28132868 DOI: 10.1016/j.jtho.2017.01.019] [Cited by in Crossref: 74] [Cited by in F6Publishing: 87] [Article Influence: 14.8] [Reference Citation Analysis]
325 van Rooijen JM, Stutvoet TS, Schröder CP, de Vries EG. Immunotherapeutic options on the horizon in breast cancer treatment. Pharmacology & Therapeutics 2015;156:90-101. [DOI: 10.1016/j.pharmthera.2015.09.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
326 Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. J Exp Clin Cancer Res 2020;39:180. [PMID: 32892748 DOI: 10.1186/s13046-020-01694-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
327 Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med 2018;24:556-62. [PMID: 29736026 DOI: 10.1038/s41591-018-0012-z] [Cited by in Crossref: 169] [Cited by in F6Publishing: 165] [Article Influence: 42.3] [Reference Citation Analysis]
328 Murakami Y, Matsumoto K, Shimizu Y, Ikeda M, Amano N, Shimura S, Ishii D, Sato Y, Iwamura M. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy. Urol Oncol 2021;39:195.e15-23. [PMID: 33071109 DOI: 10.1016/j.urolonc.2020.09.034] [Reference Citation Analysis]
329 Przespolewski AC, Portwood S, Wang ES. Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches. Leuk Lymphoma 2021;:1-10. [PMID: 34818963 DOI: 10.1080/10428194.2021.1992614] [Reference Citation Analysis]
330 Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213:2835-2840. [PMID: 27903604 DOI: 10.1084/jem.20161462] [Cited by in Crossref: 150] [Cited by in F6Publishing: 148] [Article Influence: 25.0] [Reference Citation Analysis]
331 Klein S, Mauch C, Wagener-Ryczek S, Schoemmel M, Buettner R, Quaas A, Helbig D. Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. Cancer Immunol Immunother 2019;68:973-82. [PMID: 30963193 DOI: 10.1007/s00262-019-02339-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
332 Inamura K, Shigematsu Y, Ninomiya H, Nakashima Y, Kobayashi M, Saito H, Takahashi K, Futaya E, Okumura S, Ishikawa Y, Kanda H. CSF1R-Expressing Tumor-Associated Macrophages, Smoking and Survival in Lung Adenocarcinoma: Analyses Using Quantitative Phosphor-Integrated Dot Staining. Cancers (Basel) 2018;10:E252. [PMID: 30065206 DOI: 10.3390/cancers10080252] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
333 Delmas D, Hermetet F, Aires V. PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy. Cancers (Basel) 2021;13:4509. [PMID: 34572736 DOI: 10.3390/cancers13184509] [Reference Citation Analysis]
334 Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met Ö, Hansen M, Andersen MH, Thor Straten P, Svane IM. mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology 2016;5:e1207842. [PMID: 27757300 DOI: 10.1080/2162402X.2016.1207842] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
335 Teng MW, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunoediting. J Clin Invest 2015;125:3338-46. [PMID: 26241053 DOI: 10.1172/JCI80004] [Cited by in Crossref: 157] [Cited by in F6Publishing: 83] [Article Influence: 22.4] [Reference Citation Analysis]
336 Gombos A, Awada A. Advances in chemical pharmacotherapy to manage advanced breast cancer. Expert Opin Pharmacother 2017;18:95-103. [PMID: 27927046 DOI: 10.1080/14656566.2016.1269748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
337 Bordon Y. Tumour immunology: Checkpoint parley. Nat Rev Immunol 2015;15:5. [PMID: 25475446 DOI: 10.1038/nri3792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
338 Lane RS, Femel J, Breazeale AP, Loo CP, Thibault G, Kaempf A, Mori M, Tsujikawa T, Chang YH, Lund AW. IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 2018;215:3057-74. [PMID: 30381467 DOI: 10.1084/jem.20180654] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 14.3] [Reference Citation Analysis]
339 Xi Z, Jones PS, Mikamoto M, Jiang X, Faje AT, Nie C, Labelle KE, Zhou Y, Miller KK, Soberman RJ, Zhang X. The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas. Front Endocrinol (Lausanne) 2021;12:726448. [PMID: 34745002 DOI: 10.3389/fendo.2021.726448] [Reference Citation Analysis]
340 Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity 2016;44:1255-69. [PMID: 27332730 DOI: 10.1016/j.immuni.2016.06.001] [Cited by in Crossref: 438] [Cited by in F6Publishing: 442] [Article Influence: 87.6] [Reference Citation Analysis]
341 Martins PR, Machado CMT, Coxir SA, de Oliveira AJ, Moreira TB, Campos LS, Alcântara R, de Paula SOC, de Oliveira Salles PG, Gollob KJ, Magalhães WCS. Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment. Experimental and Molecular Pathology 2019;111:104314. [DOI: 10.1016/j.yexmp.2019.104314] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
342 Perea F, Sánchez-Palencia A, Gómez-Morales M, Bernal M, Concha Á, García MM, González-Ramírez AR, Kerick M, Martin J, Garrido F, Ruiz-Cabello F, Aptsiauri N. HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget 2018;9:4120-33. [PMID: 29423109 DOI: 10.18632/oncotarget.23469] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
343 Wang L, Liu Z, Fisher KW, Ren F, Lv J, Davidson DD, Baldridge LA, Du X, Cheng L. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. Human Pathology 2018;71:20-9. [DOI: 10.1016/j.humpath.2017.07.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
344 Gandini S, Massi D, Mandalà M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2016;100:88-98. [PMID: 26895815 DOI: 10.1016/j.critrevonc.2016.02.001] [Cited by in Crossref: 200] [Cited by in F6Publishing: 197] [Article Influence: 33.3] [Reference Citation Analysis]
345 Emens LA. It's TIME for a biomarker-driven approach to cancer immunotherapy. J Immunother Cancer 2016;4:43. [PMID: 27532018 DOI: 10.1186/s40425-016-0147-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
346 Ock CY, Kim S, Keam B, Kim S, Ahn YO, Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS. Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. Oncotarget 2017;8:97920-7. [PMID: 29228662 DOI: 10.18632/oncotarget.18542] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
347 Zhao C, Pang X, Yang Z, Wang S, Deng H, Chen X. Nanomaterials targeting tumor associated macrophages for cancer immunotherapy. J Control Release 2021;341:272-84. [PMID: 34813877 DOI: 10.1016/j.jconrel.2021.11.028] [Reference Citation Analysis]
348 Palacios Calvo J, Albanell J, Rojo F, Ciruelos E, Aranda-López I, Cortés J, García-Caballero T, Martín M, López-García MÁ, Colomer R. [Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]. Rev Esp Patol 2018;51:97-109. [PMID: 29602380 DOI: 10.1016/j.patol.2017.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
349 LoRusso PM, Schalper K, Sosman J. Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. Pigment Cell Melanoma Res 2020;33:390-402. [PMID: 31705737 DOI: 10.1111/pcmr.12847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
350 Tang Y, Li Y, Zhang L, Tong G, Ou Z, Wang Z, Zhang H, Qiao G. Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report. Thorac Cancer 2020;11:1094-8. [PMID: 32077636 DOI: 10.1111/1759-7714.13361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
351 Molinero L, Li Y, Chang CW, Maund S, Berg M, Harrison J, Fassò M, O'Hear C, Hegde P, Emens LA. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer 2019;7:274. [PMID: 31647026 DOI: 10.1186/s40425-019-0740-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
352 Chen G, Kim YH, Li H, Luo H, Liu DL, Zhang ZJ, Lay M, Chang W, Zhang YQ, Ji RR. PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat Neurosci 2017;20:917-26. [PMID: 28530662 DOI: 10.1038/nn.4571] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 15.2] [Reference Citation Analysis]
353 Blessin NC, Li W, Mandelkow T, Jansen HL, Yang C, Raedler JB, Simon R, Büscheck F, Dum D, Luebke AM, Hinsch A, Möller K, Menz A, Bernreuther C, Lebok P, Clauditz T, Sauter G, Marx A, Uhlig R, Wilczak W, Minner S, Krech T, Fraune C, Höflmayer D, Burandt E, Steurer S. Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers. Cell Oncol (Dordr) 2021;44:793-803. [PMID: 33864611 DOI: 10.1007/s13402-021-00601-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
354 Mizugaki H, Yamamoto N, Murakami H, Kenmotsu H, Fujiwara Y, Ishida Y, Kawakami T, Takahashi T. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest New Drugs 2016;34:596-603. [PMID: 27363843 DOI: 10.1007/s10637-016-0371-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
355 Li X, Lian Z, Wang S, Xing L, Yu J. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. Cancer Letters 2018;418:1-9. [DOI: 10.1016/j.canlet.2018.01.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
356 Zhang AW, Mcpherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CP, Laan S, Ledoux S, Cochrane DR, Lim JL, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan AN, Nielsen CB, Huebner C, Tessier-cloutier B, Anglesio MS, Bouchard-côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, Mcalpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell 2018;173:1755-1769.e22. [DOI: 10.1016/j.cell.2018.03.073] [Cited by in Crossref: 140] [Cited by in F6Publishing: 115] [Article Influence: 35.0] [Reference Citation Analysis]
357 Naidoo J, Li BT, Schindler K, Page DB. What does the future hold for immunotherapy in cancer? Ann Transl Med 2016;4:177. [PMID: 27275490 DOI: 10.21037/atm.2016.04.05] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
358 Xu S, Sharma UC, Tuttle C, Pokharel S. Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. Front Cardiovasc Med 2021;8:619650. [PMID: 33614750 DOI: 10.3389/fcvm.2021.619650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
359 Kwak M, Erdag G, Slingluff CL Jr. Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. Sci Rep 2020;10:18336. [PMID: 33110110 DOI: 10.1038/s41598-020-74996-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
360 Wang T, Wu X, Guo C, Zhang K, Xu J, Li Z, Jiang S. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. J Med Chem 2019;62:1715-30. [PMID: 30247903 DOI: 10.1021/acs.jmedchem.8b00990] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
361 Matsuki E, Younes A. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Curr Treat Options Oncol. 2016;17:31. [PMID: 27193488 DOI: 10.1007/s11864-016-0401-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
362 Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expr 2020;20:53-65. [PMID: 32340652 DOI: 10.3727/105221620X15880179864121] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
363 Utzschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S, Danilo M, Alfei F, Hofmann M, Wieland D, Pradervand S, Thimme R, Zehn D, Held W. T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. Immunity 2016;45:415-27. [PMID: 27533016 DOI: 10.1016/j.immuni.2016.07.021] [Cited by in Crossref: 341] [Cited by in F6Publishing: 319] [Article Influence: 68.2] [Reference Citation Analysis]
364 Kawashita S, Aoyagi K, Yamanaka H, Hantani R, Naruoka S, Tanimoto A, Hori Y, Toyonaga Y, Fukushima K, Miyazaki S, Hantani Y. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction. Bioorganic & Medicinal Chemistry Letters 2019;29:2464-7. [DOI: 10.1016/j.bmcl.2019.07.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
365 Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu C, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 2020;12:eaaz3577. [DOI: 10.1126/scitranslmed.aaz3577] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 17.5] [Reference Citation Analysis]
366 Mi Y, Han J, Zhu J, Jin T. Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. Mol Neurobiol 2021. [PMID: 34480337 DOI: 10.1007/s12035-021-02495-7] [Reference Citation Analysis]
367 Song Y, Li Z, Xue W, Zhang M. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy 2019;11:515-29. [DOI: 10.2217/imt-2018-0173] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
368 Ju A, Lee SW, Lee YE, Han KC, Kim JC, Shin SC, Park HJ, EunKyeong Kim E, Hong S, Jang M. A carrier-free multiplexed gene editing system applicable for suspension cells. Biomaterials 2019;217:119298. [PMID: 31280073 DOI: 10.1016/j.biomaterials.2019.119298] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
369 Sponaas AM, Yang R, Rustad EH, Standal T, Thoresen AS, Dao Vo C, Waage A, Slørdahl TS, Børset M, Sundan A. PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. Oncotarget 2018;9:32024-35. [PMID: 30174794 DOI: 10.18632/oncotarget.25882] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
370 Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12:208-222. [PMID: 27913228 DOI: 10.1016/j.jtho.2016.11.2228] [Cited by in Crossref: 683] [Cited by in F6Publishing: 707] [Article Influence: 113.8] [Reference Citation Analysis]
371 Chen Y, Liu Q, Chen Z, Wang Y, Yang W, Hu Y, Han W, Zeng H, Ma H, Dai J, Zhang H. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. J Exp Clin Cancer Res 2019;38:193. [PMID: 31088500 DOI: 10.1186/s13046-019-1192-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
372 Chen DS, Hurwitz H. Combinations of Bevacizumab With Cancer Immunotherapy. Cancer J. 2018;24:193-204. [PMID: 30119083 DOI: 10.1097/ppo.0000000000000327] [Cited by in Crossref: 67] [Cited by in F6Publishing: 33] [Article Influence: 22.3] [Reference Citation Analysis]
373 Bai Y, Chen X, Hou L, Qian J, Jiang T, Zhou C, Ciebiada M. PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. Cancer Biol Med 2018;15:434-42. [PMID: 30766753 DOI: 10.20892/j.issn.2095-3941.2018.0223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
374 Seetharamu N, Preeshagul IR, Sullivan KM. New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. Lung Cancer (Auckl) 2017;8:67-78. [PMID: 28761384 DOI: 10.2147/LCTT.S113177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
375 Jean F, Tomasini P, Barlesi F. Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy. Ther Adv Med Oncol 2017;9:769-79. [PMID: 29449897 DOI: 10.1177/1758834017741074] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
376 Falchook G. Nivolumab: another weapon in the growing immunotherapy arsenal. Lancet Oncol 2015;16:350-1. [PMID: 25795404 DOI: 10.1016/S1470-2045(15)70109-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
377 Zou Y, Chen Z, Han H, Ruan S, Jin L, Zhang Y, Chen Z, Ma Z, Lou Q, Shi N, Jin H. Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8+ T Cell Infiltration. Front Mol Biosci 2021;8:602227. [PMID: 33816550 DOI: 10.3389/fmolb.2021.602227] [Reference Citation Analysis]
378 Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res 2015;3:1148-57. [PMID: 26014098 DOI: 10.1158/2326-6066.CIR-15-0059] [Cited by in Crossref: 249] [Cited by in F6Publishing: 151] [Article Influence: 35.6] [Reference Citation Analysis]
379 Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. NPJ Breast Cancer 2016;2:16002. [PMID: 28721372 DOI: 10.1038/npjbcancer.2016.2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
380 Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017;8:1597. [PMID: 29255458 DOI: 10.3389/fimmu.2017.01597] [Cited by in Crossref: 116] [Cited by in F6Publishing: 114] [Article Influence: 23.2] [Reference Citation Analysis]
381 Malik P, Mukherjee TK. Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers. International Journal of Pharmaceutics 2018;553:483-509. [DOI: 10.1016/j.ijpharm.2018.10.048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
382 Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, Tamura K, Hamada A. A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. Sci Rep 2016;6:19772. [PMID: 26813960 DOI: 10.1038/srep19772] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
383 Kottschade L, Brys A, Peikert T, Ryder M, Raffals L, Brewer J, Mosca P, Markovic S; Midwest Melanoma Partnership. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res 2016;26:469-80. [PMID: 27306502 DOI: 10.1097/CMR.0000000000000273] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
384 Lu Z, Chen H, Jiao X, Wang Y, Wu L, Sun H, Li S, Gong J, Li J, Zou J, Yang K, Hu Y, Mao B, Zhang L, Zhang X, Peng Z, Lu M, Wang Z, Zhang H, Shen L. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. Genome Med 2021;13:175. [PMID: 34732240 DOI: 10.1186/s13073-021-00997-6] [Reference Citation Analysis]
385 Kampan NC, Madondo MT, McNally OM, Stephens AN, Quinn MA, Plebanski M. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. Front Immunol 2017;8:1482. [PMID: 29163543 DOI: 10.3389/fimmu.2017.01482] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
386 Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med 2019;25:929-35. [DOI: 10.1038/s41591-019-0474-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 90] [Article Influence: 32.7] [Reference Citation Analysis]
387 Wolf GT, Liu S, Bellile E, Sartor M, Rozek L, Thomas D, Nguyen A, Zarins K, McHugh JB; INSPIRE Trial Clinical Investigators. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. Oral Oncol 2020;111:104928. [PMID: 32738599 DOI: 10.1016/j.oraloncology.2020.104928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
388 Kudo M. Pembrolizumab for the Treatment of Hepatocellular Carcinoma. Liver Cancer 2019;8:143-54. [PMID: 31192152 DOI: 10.1159/000500143] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
389 Cheng W, Fu D, Xu F, Zhang Z. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. Oncogenesis 2018;7:2. [PMID: 29358573 DOI: 10.1038/s41389-017-0013-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
390 Liao X, Zhao L, Wu S, Zheng H, Chen H, Zhang H, Wang Z, Lin Q. Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance. Oncotarget 2017;8:113287-93. [PMID: 29348907 DOI: 10.18632/oncotarget.22938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
391 Lou W, Gao K, Xu C, Li Q. Bromodomain-containing protein 9 is a prognostic biomarker associated with immune infiltrates and promotes tumor malignancy through activating notch signaling pathway in negative HIF-2α clear cell renal cell carcinoma. IUBMB Life 2021;73:1334-47. [PMID: 34415102 DOI: 10.1002/iub.2547] [Reference Citation Analysis]
392 Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015;4:e1008814. [PMID: 26137403 DOI: 10.1080/2162402X.2015.1008814] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 9.3] [Reference Citation Analysis]
393 Roviello G, D’angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini ND, Sobhani N. Avelumab in gastric cancer. Immunotherapy 2019;11:759-68. [DOI: 10.2217/imt-2019-0011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
394 Paciotti R, Agamennone M, Coletti C, Storchi L. Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach. J Comput Aided Mol Des 2020;34:897-914. [PMID: 32185582 DOI: 10.1007/s10822-020-00306-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
395 Mari L, Hoefnagel SJM, Zito D, van de Meent M, van Endert P, Calpe S, Sancho Serra MDC, Heemskerk MHM, van Laarhoven HWM, Hulshof MCCM, Gisbertz SS, Medema JP, van Berge Henegouwen MI, Meijer SL, Bergman JJGHM, Milano F, Krishnadath KK. microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients. Gastroenterology 2018;155:784-98. [PMID: 29885883 DOI: 10.1053/j.gastro.2018.06.030] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
396 Hamilton EP, Kaklamani V, Falkson C, Vidal GA, Ward PJ, Patre M, Chui SY, Rotmensch J, Gupta K, Molinero L, Li Y, Emens LA. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. Clin Breast Cancer 2021:S1526-8209(21)00089-6. [PMID: 34154926 DOI: 10.1016/j.clbc.2021.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
397 Miao L, Li J, Liu Q, Feng R, Das M, Lin CM, Goodwin TJ, Dorosheva O, Liu R, Huang L. Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. ACS Nano 2017;11:8690-706. [PMID: 28809532 DOI: 10.1021/acsnano.7b01786] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 14.8] [Reference Citation Analysis]
398 Schouten RD, Muller M, de Gooijer CJ, Baas P, van den Heuvel M. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute. Lung Cancer 2018;126:210-6. [PMID: 29179916 DOI: 10.1016/j.lungcan.2017.11.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
399 Marcion G, Hermetet F, Neiers F, Uyanik B, Dondaine L, Dias AMM, Da Costa L, Moreau M, Bellaye PS, Collin B, Gobbo J, Briand L, Seigneuric R, Kitten O, Cinier M, Garrido C. Nanofitins targeting heat shock protein 110: An innovative immunotherapeutic modality in cancer. Int J Cancer 2021;148:3019-31. [PMID: 33506516 DOI: 10.1002/ijc.33485] [Reference Citation Analysis]
400 Liu Y, Wu M, Zhang Y, Luo Y, He S, Wang Y, Chen F, Liu Y, Yang Q, Li Y, Wei H, Zhang H, Jin C, Lu N, Li W, Wang S, Guo Y, Ye Z. Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. Front Oncol 2021;11:657615. [PMID: 33816314 DOI: 10.3389/fonc.2021.657615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
401 Glorieux C, Xia X, He YQ, Hu Y, Cremer K, Robert A, Liu J, Wang F, Ling J, Chiao PJ, Huang P. Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling. Redox Biol 2021;38:101780. [PMID: 33171331 DOI: 10.1016/j.redox.2020.101780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
402 Zheng L. PD-L1 Expression in Pancreatic Cancer. J Natl Cancer Inst. 2017;109. [PMID: 28131993 DOI: 10.1093/jnci/djw304] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
403 Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell. 2017;168:487-502.e15. [PMID: 28111070 DOI: 10.1016/j.cell.2016.12.022] [Cited by in Crossref: 408] [Cited by in F6Publishing: 370] [Article Influence: 81.6] [Reference Citation Analysis]
404 Devereaux KA, Charu V, Zhao S, Charville GW, Bangs CD, van de Rijn M, Cherry AM, Natkunam Y. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies. Hum Pathol 2018;82:39-45. [PMID: 30539796 DOI: 10.1016/j.humpath.2018.06.034] [Reference Citation Analysis]
405 Tsuyuki Y, Ishikawa E, Kohno K, Shimada K, Ohka F, Suzuki Y, Mabuchi S, Satou A, Takahara T, Kato S, Miyagi S, Ozawa H, Kawano T, Takagi Y, Hiraga J, Wakabayashi T, Nakamura S. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system. Neuropathology 2021;41:99-108. [PMID: 33269495 DOI: 10.1111/neup.12705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
406 [DOI: 10.1101/2020.04.28.066639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
407 Ochoa de Olza M, Oliva M, Hierro C, Matos I, Martin-Liberal J, Garralda E. Early-drug development in the era of immuno-oncology: are we ready to face the challenges? Ann Oncol 2018;29:1727-40. [PMID: 29945232 DOI: 10.1093/annonc/mdy225] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
408 Lim JCT, Yeong JPS, Lim CJ, Ong CCH, Wong SC, Chew VSP, Ahmed SS, Tan PH, Iqbal J. An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use. Pathology 2018;50:333-41. [PMID: 29429740 DOI: 10.1016/j.pathol.2017.11.087] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
409 Ruan S, Xie R, Qin L, Yu M, Xiao W, Hu C, Yu W, Qian Z, Ouyang L, He Q, Gao H. Aggregable Nanoparticles-Enabled Chemotherapy and Autophagy Inhibition Combined with Anti-PD-L1 Antibody for Improved Glioma Treatment. Nano Lett 2019;19:8318-32. [DOI: 10.1021/acs.nanolett.9b03968] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 15.7] [Reference Citation Analysis]
410 Villanueva N, Bazhenova L. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis 2018;12:1753466618794133. [PMID: 30215300 DOI: 10.1177/1753466618794133] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
411 Chae YK, Oh MS, Giles FJ. Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. Oncologist 2018;23:410-21. [PMID: 29242279 DOI: 10.1634/theoncologist.2017-0354] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
412 Sato F, Ono T, Kawahara A, Kawaguchi T, Tanaka H, Shimamatsu K, Kakuma T, Akiba J, Umeno H, Yano H. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. J Clin Pathol 2019;72:542-9. [PMID: 31113825 DOI: 10.1136/jclinpath-2019-205818] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
413 Zwaenepoel K, Jacobs J, De Meulenaere A, Silence K, Smits E, Siozopoulou V, Hauben E, Rolfo C, Rottey S, Pauwels P. CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy. Histopathology 2017;71:357-65. [PMID: 28383817 DOI: 10.1111/his.13230] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
414 Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi F, Oxnard GR, Jackman DM, Jänne PA. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. Journal of Thoracic Oncology 2015;10:1726-35. [DOI: 10.1097/jto.0000000000000687] [Cited by in Crossref: 130] [Cited by in F6Publishing: 75] [Article Influence: 18.6] [Reference Citation Analysis]
415 Liu X, Hogg GD, DeNardo DG. Rethinking immune checkpoint blockade: 'Beyond the T cell'. J Immunother Cancer 2021;9:e001460. [PMID: 33468555 DOI: 10.1136/jitc-2020-001460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
416 Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 2017;9:eaak9679. [DOI: 10.1126/scitranslmed.aak9679] [Reference Citation Analysis]
417 Budczies J, Bockmayr M, Denkert C, Klauschen F, Gröschel S, Darb-Esfahani S, Pfarr N, Leichsenring J, Onozato ML, Lennerz JK, Dietel M, Fröhling S, Schirmacher P, Iafrate AJ, Weichert W, Stenzinger A. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. Genes Chromosomes Cancer 2016;55:626-39. [PMID: 27106868 DOI: 10.1002/gcc.22365] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
418 Lopez J, Harris S, Roda D, Yap TA. Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Transl Oncogenomics 2015;7:1-11. [PMID: 26609214 DOI: 10.4137/TOG.S30533] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
419 Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 2016;41:23-31. [PMID: 27240055 DOI: 10.1016/j.coi.2016.05.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 11.2] [Reference Citation Analysis]
420 Shao Z, Wang AZ, George DJ, Zhang T. Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. Asian J Urol 2016;3:268-77. [PMID: 29264195 DOI: 10.1016/j.ajur.2016.08.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
421 Liao R, Ma QZ, Zhou CY, Li JJ, Weng NN, Yang Y, Zhu Q. Identification of biomarkers related to Tumor-Infiltrating Lymphocytes (TILs) infiltration with gene co-expression network in colorectal cancer. Bioengineered 2021;12:1676-88. [PMID: 33960283 DOI: 10.1080/21655979.2021.1921551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
422 Luo F, Luo M, Rong QX, Zhang H, Chen Z, Wang F, Zhao HY, Fu LW. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. J Immunother Cancer 2019;7:245. [PMID: 31511071 DOI: 10.1186/s40425-019-0733-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
423 Hama N, Kobayashi T, Han N, Kitagawa F, Kajihara N, Otsuka R, Wada H, Lee HK, Rhee H, Hasegawa Y, Yagita H, Baghdadi M, Seino KI. Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade. iScience 2020;23:101584. [PMID: 33205010 DOI: 10.1016/j.isci.2020.101584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
424 McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016;2:46-54. [PMID: 26562159 DOI: 10.1001/jamaoncol.2015.3638] [Cited by in Crossref: 431] [Cited by in F6Publishing: 460] [Article Influence: 71.8] [Reference Citation Analysis]
425 Ben Shimol J, Guzman-Prado Y, Karlinskaya M, Davidson T. Effectiveness and safety of immune checkpoint inhibitors in combination with palliative radiotherapy in advanced melanoma: A systematic review. Crit Rev Oncol Hematol 2021;167:103499. [PMID: 34687896 DOI: 10.1016/j.critrevonc.2021.103499] [Reference Citation Analysis]
426 Schumacher TN, Kesmir C, van Buuren MM. Biomarkers in cancer immunotherapy. Cancer Cell 2015;27:12-4. [PMID: 25584891 DOI: 10.1016/j.ccell.2014.12.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 11.7] [Reference Citation Analysis]
427 Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, Dal Bo M. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev Clin Pharmacol 2019;12:453-70. [PMID: 30907177 DOI: 10.1080/17512433.2019.1598859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
428 Takada K, Okamoto T, Tominaga M, Teraishi K, Akamine T, Takamori S, Katsura M, Toyokawa G, Shoji F, Okamoto M, Oda Y, Hoshino T, Maehara Y. Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. PLoS One 2017;12:e0181598. [PMID: 28727766 DOI: 10.1371/journal.pone.0181598] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
429 Diesendruck Y, Benhar I. Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges. Drug Resistance Updates 2017;30:39-47. [DOI: 10.1016/j.drup.2017.02.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
430 Vilgelm AE, Johnson DB, Richmond A. Combinatorial approach to cancer immunotherapy: strength in numbers. J Leukoc Biol 2016;100:275-90. [PMID: 27256570 DOI: 10.1189/jlb.5RI0116-013RR] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
431 Ioannou N, Hagner PR, Stokes M, Gandhi AK, Apollonio B, Fanous M, Papazoglou D, Sutton LA, Rosenquist R, Amini RM, Chiu H, Lopez-Girona A, Janardhanan P, Awan FT, Jones J, Kay NE, Shanafelt TD, Tallman MS, Stamatopoulos K, Patten PEM, Vardi A, Ramsay AG. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood 2021;137:216-31. [PMID: 33024998 DOI: 10.1182/blood.2020006073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
432 Mony JT, Zhang L, Ma T, Grabosch S, Tirodkar TS, Brozick J, Tseng G, Elishaev E, Edwards RP, Huang X, Vlad AM. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunol Immunother 2015;64:1095-108. [PMID: 25998800 DOI: 10.1007/s00262-015-1712-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
433 Young MH, Pietz G, Whalen E, Copeland W, Thompson E, Fox BA, Newhall KJ. Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. Sci Rep 2021;11:16460. [PMID: 34385543 DOI: 10.1038/s41598-021-95902-x] [Reference Citation Analysis]
434 Braun DA, Wu CJ. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer J 2017;23:115-24. [PMID: 28410299 DOI: 10.1097/PPO.0000000000000257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
435 Giraldo NA, Peske JD, Sautès-fridman C, Fridman WH. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Arch 2019;474:463-74. [DOI: 10.1007/s00428-018-02517-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
436 Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 2018;31:214-34. [PMID: 29192647 DOI: 10.1038/modpathol.2017.156] [Cited by in Crossref: 136] [Cited by in F6Publishing: 138] [Article Influence: 27.2] [Reference Citation Analysis]
437 Buder-Bakhaya K, Hassel JC. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond. Front Immunol 2018;9:1474. [PMID: 30002656 DOI: 10.3389/fimmu.2018.01474] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 26.0] [Reference Citation Analysis]
438 Pavlick AC, Fecher L, Ascierto PA, Sullivan RJ. Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer? Am Soc Clin Oncol Educ Book 2019;39:564-71. [PMID: 31099689 DOI: 10.1200/EDBK_243071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
439 Shang X, Li Z, Sun J, Zhao C, Lin J, Wang H. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab. Lung Cancer 2021;154:105-12. [PMID: 33640623 DOI: 10.1016/j.lungcan.2021.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
440 Kunert A, Chmielewski M, Wijers R, Berrevoets C, Abken H, Debets R. Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. Oncoimmunology 2017;7:e1378842. [PMID: 29296541 DOI: 10.1080/2162402X.2017.1378842] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
441 Watanabe M, Kuwata T, Setsuda A, Tokunaga M, Kaito A, Sugita S, Tonouchi A, Kinoshita T, Nagino M. Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry. Sci Rep 2021;11:4165. [PMID: 33603111 DOI: 10.1038/s41598-021-83711-1] [Reference Citation Analysis]
442 Otoshi T, Nagano T, Tachihara M, Nishimura Y. Possible Biomarkers for Cancer Immunotherapy. Cancers (Basel) 2019;11:E935. [PMID: 31277279 DOI: 10.3390/cancers11070935] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
443 Sundar R, Huang KK, Qamra A, Kim KM, Kim ST, Kang WK, Tan ALK, Lee J, Tan P. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Ann Oncol. 2019;30:424-430. [PMID: 30624548 DOI: 10.1093/annonc/mdy550] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
444 Imbimbo M, Lo Russo G, Blackhall F. Current Status of Immunotherapy for Non-Small-Cell Lung Cancer. Tumori 2016;102:337-51. [DOI: 10.5301/tj.5000537] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
445 Jin J, Si J, Liu Y, Wang H, Ni R, Wang J. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. Respir Res 2018;19:197. [PMID: 30290817 DOI: 10.1186/s12931-018-0885-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
446 Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, Vranic S, Gatalica Z. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med 2019;8:7322-9. [PMID: 31609094 DOI: 10.1002/cam4.2602] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
447 Ali HR, Dariush A, Provenzano E, Bardwell H, Abraham JE, Iddawela M, Vallier AL, Hiller L, Dunn JA, Bowden SJ, Hickish T, McAdam K, Houston S, Irwin MJ, Pharoah PD, Brenton JD, Walton NA, Earl HM, Caldas C. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res 2016;18:21. [PMID: 26882907 DOI: 10.1186/s13058-016-0682-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
448 Hu B, Xiao J, Xiu Y, Fu Z, Shi H, Cheng D. Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma: . Nuclear Medicine Communications 2020;41:252-9. [DOI: 10.1097/mnm.0000000000001136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
449 Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14:655-668. [PMID: 28653677 DOI: 10.1038/nrclinonc.2017.88] [Cited by in Crossref: 373] [Cited by in F6Publishing: 350] [Article Influence: 74.6] [Reference Citation Analysis]
450 Green MA, Waddell JA, Solimando DA Jr. Drug Monographs: Atezolizumab and Everolimus. Hosp Pharm 2016;51:810-4. [PMID: 27928185 DOI: 10.1310/hpj5110-810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
451 Tsukita Y, Miyauchi E, Fukudo M, Sasaki T, Ichinose M. Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab. Eur J Cancer 2020;133:22-4. [PMID: 32422505 DOI: 10.1016/j.ejca.2020.04.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Peper JK, Stevanović S. A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy. Cancer Immunol Immunother 2015;64:1295-303. [PMID: 25822767 DOI: 10.1007/s00262-015-1682-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
453 Cook AM, Lesterhuis WJ, Nowak AK, Lake RA. Chemotherapy and immunotherapy: mapping the road ahead. Curr Opin Immunol 2016;39:23-9. [PMID: 26724433 DOI: 10.1016/j.coi.2015.12.003] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 10.7] [Reference Citation Analysis]
454 Jeon IS, Yoo JD, Gurung S, Kim M, Lee C, Park EJ, Park RW, Lee B, Kim S. Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs. Biomaterials 2021;270:120685. [PMID: 33524811 DOI: 10.1016/j.biomaterials.2021.120685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
455 Picardo SL, Doi J, Hansen AR. Structure and Optimization of Checkpoint Inhibitors. Cancers (Basel) 2019;12:E38. [PMID: 31877721 DOI: 10.3390/cancers12010038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
456 George JT, Levine H. Stochastic modeling of tumor progression and immune evasion. J Theor Biol 2018;458:148-55. [PMID: 30218648 DOI: 10.1016/j.jtbi.2018.09.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
457 Chen Z, Chen J, Ren D, Zhang J, Yang Y, Zhang H, Mao B, Ma H. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma. Aging (Albany NY) 2020;13:598-618. [PMID: 33288738 DOI: 10.18632/aging.202169] [Reference Citation Analysis]
458 Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, Guo J, Huang YH, Fan C, Ren S, Sun Y, Freeman GJ, Sicinski P, Wei W. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 2018;553:91-5. [PMID: 29160310 DOI: 10.1038/nature25015] [Cited by in Crossref: 287] [Cited by in F6Publishing: 283] [Article Influence: 57.4] [Reference Citation Analysis]
459 Martin D, Rödel F, Balermpas P, Rödel C, Fokas E. The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2017;1868:221-30. [DOI: 10.1016/j.bbcan.2017.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
460 Shen X, Zhang L, Li J, Li Y, Wang Y, Xu ZX. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Front Immunol 2019;10:1337. [PMID: 31258527 DOI: 10.3389/fimmu.2019.01337] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 16.7] [Reference Citation Analysis]
461 Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 2021;18:345-62. [PMID: 33580222 DOI: 10.1038/s41571-021-00473-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 27.0] [Reference Citation Analysis]
462 Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021; 13(7): 795-824 [PMID: 34367478 DOI: 10.4252/wjsc.v13.i7.795] [Reference Citation Analysis]
463 El Jabbour T, Ross JS, Sheehan CE, Affolter KE, Geiersbach KB, Boguniewicz A, Ainechi S, Bronner MP, Jones DM, Lee H. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. J Clin Pathol 2018;71:46-51. [PMID: 28667193 DOI: 10.1136/jclinpath-2017-204525] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
464 Feng M, Xiong G, Cao Z, Yang G, Zheng S, Song X, You L, Zheng L, Zhang T, Zhao Y. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Lett. 2017;407:57-65. [PMID: 28826722 DOI: 10.1016/j.canlet.2017.08.006] [Cited by in Crossref: 113] [Cited by in F6Publishing: 108] [Article Influence: 22.6] [Reference Citation Analysis]
465 Hinterleitner C, Strähle J, Malenke E, Hinterleitner M, Henning M, Seehawer M, Bilich T, Heitmann J, Lutz M, Mattern S, Scheuermann S, Horger M, Maurer S, Walz J, Fend F, Handgretinger R, Seitz C, Weigelin B, Singer S, Salih H, Borst O, Kopp HG, Zender L. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun 2021;12:7005. [PMID: 34853305 DOI: 10.1038/s41467-021-27303-7] [Reference Citation Analysis]
466 Chen RY, Lin YC, Shen WC, Hsieh TC, Yen KY, Chen SW, Kao CH. Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck. Sci Rep 2018;8:105. [PMID: 29311707 DOI: 10.1038/s41598-017-18489-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
467 Passiglia F, Bronte G, Bazan V, Natoli C, Rizzo S, Galvano A, Listì A, Cicero G, Rolfo C, Santini D, Russo A. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget 2016;7:19738-47. [PMID: 26918451 DOI: 10.18632/oncotarget.7582] [Cited by in Crossref: 87] [Cited by in F6Publishing: 93] [Article Influence: 17.4] [Reference Citation Analysis]
468 Trujillo JA, Sweis RF, Bao R, Luke JJ. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 2018;6:990-1000. [PMID: 30181337 DOI: 10.1158/2326-6066.CIR-18-0277] [Cited by in Crossref: 150] [Cited by in F6Publishing: 101] [Article Influence: 50.0] [Reference Citation Analysis]
469 Nakayama Y, Mimura K, Kua L, Okayama H, Min AKT, Saito K, Hanayama H, Watanabe Y, Saito M, Momma T, Saze Z, Ohki S, Suzuki Y, Ichikawa D, Yong W, Kono K. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. Gastric Cancer 2020;23:961-73. [DOI: 10.1007/s10120-020-01079-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
470 Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One. 2015;10:e0130142. [PMID: 26086854 DOI: 10.1371/journal.pone.0130142] [Cited by in Crossref: 294] [Cited by in F6Publishing: 283] [Article Influence: 42.0] [Reference Citation Analysis]
471 Assi HI, Kamphorst AO, Moukalled NM, Ramalingam SS. Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer 2018;124:248-61. [PMID: 29211297 DOI: 10.1002/cncr.31105] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
472 Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res 2017;5:12. [PMID: 28331612 DOI: 10.1186/s40364-017-0093-8] [Cited by in Crossref: 108] [Cited by in F6Publishing: 109] [Article Influence: 21.6] [Reference Citation Analysis]
473 Kitano S, Nakayama T, Yamashita M. Biomarkers for Immune Checkpoint Inhibitors in Melanoma. Front Oncol 2018;8:270. [PMID: 30073150 DOI: 10.3389/fonc.2018.00270] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
474 Clotman K, Janssens K, Specenier P, Weets I, De Block CEM. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2018;103:3144-3154. [PMID: 29955867 DOI: 10.1210/jc.2018-00728] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 24.3] [Reference Citation Analysis]
475 Victoor J, Borght SV, Spans L, Lehnert S, Brems H, Laenen A, Vergote I, Van Gorp T, Van Nieuwenhuysen E, Han S, Timmerman S, Van Rompuy AS, Vanden Bempt I. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study. Gynecol Oncol 2021;162:694-701. [PMID: 34253388 DOI: 10.1016/j.ygyno.2021.06.030] [Reference Citation Analysis]
476 Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Higuchi R, Amemiya K, Okimoto K, Oyama T, Mochizuki H, Omata M. New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. Oncotarget. 2018;9:10635-10649. [PMID: 29535832 DOI: 10.18632/oncotarget.24365] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
477 Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, Kim JH, Choe JH, Shin JH, Hahn SY, Oh YL, Chung JH. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 2017;24:97-106. [PMID: 28093480 DOI: 10.1530/ERC-16-0421] [Cited by in Crossref: 61] [Cited by in F6Publishing: 37] [Article Influence: 15.3] [Reference Citation Analysis]
478 Shen T, Chen Z, Zhao ZJ, Wu J. Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer. Oncotarget 2017;8:60975-86. [PMID: 28977839 DOI: 10.18632/oncotarget.17689] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
479 Ebert PJR, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M, Gould SE, Maecker H, Irving BA, Kim JM, Belvin M, Mellman I. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity. 2016;44:609-621. [PMID: 26944201 DOI: 10.1016/j.immuni.2016.01.024] [Cited by in Crossref: 357] [Cited by in F6Publishing: 322] [Article Influence: 59.5] [Reference Citation Analysis]
480 Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim C, Jeon YK. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch 2016;469:581-90. [DOI: 10.1007/s00428-016-2011-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
481 Bissonnette RP, Cesario RM, Goodenow B, Shojaei F, Gillings M. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors. BMC Cancer 2021;21:969. [PMID: 34461854 DOI: 10.1186/s12885-021-08702-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
482 Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016;1:e89829. [PMID: 27777979 DOI: 10.1172/jci.insight.89829] [Cited by in Crossref: 283] [Cited by in F6Publishing: 263] [Article Influence: 47.2] [Reference Citation Analysis]
483 Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, Momtazi-Borojeni AA, Chen S. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer 2021;9:e001698. [PMID: 33472857 DOI: 10.1136/jitc-2020-001698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
484 Filipovic A, Miller G, Bolen J. Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. Front Cell Dev Biol 2020;8:155. [PMID: 32258034 DOI: 10.3389/fcell.2020.00155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
485 Ramelow J, Brooks CD, Gao L, Almiman AA, Williams TM, Villalona-Calero MA, Duan W. The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. BMC Cancer 2020;20:738. [PMID: 32770960 DOI: 10.1186/s12885-020-07212-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
486 Marin JJG, Macias RIR, Monte MJ, Romero MR, Asensio M, Sanchez-Martin A, Cives-Losada C, Temprano AG, Espinosa-Escudero R, Reviejo M, Bohorquez LH, Briz O. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1663. [PMID: 32585893 DOI: 10.3390/cancers12061663] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
487 Po JW, Ma Y, Balakrishna B, Brungs D, Azimi F, de Souza P, Becker TM. Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. PLoS One 2019;14:e0211866. [PMID: 30735560 DOI: 10.1371/journal.pone.0211866] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
488 Safi M, Ahmed H, Al-Azab M, Xia YL, Shan X, Al-Radhi M, Al-Danakh A, Shopit A, Liu J. PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. J Adv Res 2021;29:45-54. [PMID: 33842004 DOI: 10.1016/j.jare.2020.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
489 Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol 2016;34:4102-9. [PMID: 27863197 DOI: 10.1200/JCO.2016.67.2477] [Cited by in Crossref: 347] [Cited by in F6Publishing: 200] [Article Influence: 57.8] [Reference Citation Analysis]
490 Westhoff MA, Marschall N, Debatin KM. Novel Approaches to Apoptosis-Inducing Therapies. Adv Exp Med Biol 2016;930:173-204. [PMID: 27558822 DOI: 10.1007/978-3-319-39406-0_8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
491 Juergens RA, Zukotynski KA, Singnurkar A, Snider DP, Valliant JF, Gulenchyn KY. Imaging Biomarkers in Immunotherapy. Biomark Cancer 2016;8:1-13. [PMID: 26949344 DOI: 10.4137/BIC.S31805] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
492 Pennock GK, Chow LQ. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist. 2015;20:812-822. [PMID: 26069281 DOI: 10.1634/theoncologist.2014-0422] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 15.4] [Reference Citation Analysis]
493 Szadai L, Velasquez E, Szeitz B, Almeida NP, Domont G, Betancourt LH, Gil J, Marko-Varga M, Oskolas H, Jánosi ÁJ, Boyano-Adánez MDC, Kemény L, Baldetorp B, Malm J, Horvatovich P, Szász AM, Németh IB, Marko-Varga G. Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out. Cancers (Basel) 2021;13:6105. [PMID: 34885218 DOI: 10.3390/cancers13236105] [Reference Citation Analysis]
494 Schmidinger M. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. Curr Opin Urol 2018;28:29-34. [PMID: 29045250 DOI: 10.1097/MOU.0000000000000456] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
495 Ihle CL, Owens P. Integrating the immune microenvironment of prostate cancer induced bone disease. Mol Carcinog 2020;59:822-9. [PMID: 32233011 DOI: 10.1002/mc.23192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
496 Lin Z, Xu Y, Zhang Y, He Q, Zhang J, He J, Liang W. The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures. Oncotarget 2016;7:15033-46. [PMID: 26930715 DOI: 10.18632/oncotarget.7590] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
497 Beg AA, Gray JE. HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types? Epigenomics 2016;8:1015-7. [PMID: 27410519 DOI: 10.2217/epi-2016-0066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
498 Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM, Easton V, Pollex E, Deurloo R, Dent R. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol 2019;15:1951-61. [PMID: 30977385 DOI: 10.2217/fon-2019-0059] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
499 Wieder T, Eigentler T, Brenner E, Röcken M. Immune checkpoint blockade therapy. J Allergy Clin Immunol 2018;142:1403-14. [PMID: 29596939 DOI: 10.1016/j.jaci.2018.02.042] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
500 Deshpande RP, Sharma S, Watabe K. The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers (Basel) 2020;12:E2983. [PMID: 33076303 DOI: 10.3390/cancers12102983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
501 Chen SC, Chang PM, Wang HJ, Tai SK, Chu PY, Yang MH. PD-L1 expression is associated with p16INK4A expression in non-oropharyngeal head and neck squamous cell carcinoma. Oncol Lett 2018;15:2259-65. [PMID: 29434933 DOI: 10.3892/ol.2017.7564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
502 Zemek RM, De Jong E, Chin WL, Schuster IS, Fear VS, Casey TH, Forbes C, Dart SJ, Leslie C, Zaitouny A, Small M, Boon L, Forrest ARR, Muiri DO, Degli-Esposti MA, Millward MJ, Nowak AK, Lassmann T, Bosco A, Lake RA, Lesterhuis WJ. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Sci Transl Med 2019;11:eaav7816. [PMID: 31316010 DOI: 10.1126/scitranslmed.aav7816] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 26.5] [Reference Citation Analysis]
503 Feng E, Zheng T, He X, Chen J, Tian Y. A novel ternary heterostructure with dramatic SERS activity for evaluation of PD-L1 expression at the single-cell level. Sci Adv 2018;4:eaau3494. [PMID: 30406203 DOI: 10.1126/sciadv.aau3494] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
504 Lotfinejad P, Kazemi T, Safaei S, Amini M, Roshani Asl E, Baghbani E, Sandoghchian Shotorbani S, Jadidi Niaragh F, Derakhshani A, Abdoli Shadbad M, Silvestris N, Baradaran B. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. Biomed Pharmacother 2021;138:111436. [PMID: 33667790 DOI: 10.1016/j.biopha.2021.111436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
505 Lane RS, Lund AW. Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. Front Immunol 2018;9:2662. [PMID: 30498499 DOI: 10.3389/fimmu.2018.02662] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
506 Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology 2016;5:e1106127. [PMID: 26942094 DOI: 10.1080/2162402X.2015.1106127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
507 Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol 2019;5:74-82. [PMID: 30242306 DOI: 10.1001/jamaoncol.2018.4224] [Cited by in Crossref: 234] [Cited by in F6Publishing: 224] [Article Influence: 78.0] [Reference Citation Analysis]
508 Chuang J, Chao J, Hendifar A, Klempner SJ, Gong J. Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. Transl Gastroenterol Hepatol 2019;4:63. [PMID: 31559344 DOI: 10.21037/tgh.2019.08.04] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
509 Andreis TF, Correa BS, Vianna FS, De-Paris F, Siebert M, Leistner-Segal S, Hahn EC, Ulbrich JM, Rivero LFR, De Oliveira FH, Lorandi V, Ashton-Prolla P, Macedo GS. Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country. J Glob Oncol 2019;5:1-9. [PMID: 31532708 DOI: 10.1200/JGO.19.00174] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
510 Wei M, Liu X, Cao C, Yang J, Lv Y, Huang J, Wang Y, Qin Y. An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma. BMB Rep 2018;51:572-7. [DOI: 10.5483/bmbrep.2018.51.11.076] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
511 Lieberman NA, Moyes KW, Crane CA. Developing immunotherapeutic strategies to target brain tumors. Expert Rev Anticancer Ther 2016;16:775-88. [PMID: 27253692 DOI: 10.1080/14737140.2016.1192470] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
512 Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M. Immunotherapeutic Advances for NSCLC. Biologics 2021;15:399-417. [PMID: 34675481 DOI: 10.2147/BTT.S295406] [Reference Citation Analysis]
513 Hasegawa S, Kobayashi N, Okubo N, Tokuhisa M, Goto A, Kurita Y, Sato T, Hosono K, Endo I, Nakajima A, Ichikawa Y. Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms. Intern Med 2021;60:977-83. [PMID: 33162477 DOI: 10.2169/internalmedicine.5648-20] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
514 Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol 2019;5:195-203. [PMID: 30383184 DOI: 10.1001/jamaoncol.2018.4628] [Cited by in Crossref: 96] [Cited by in F6Publishing: 99] [Article Influence: 32.0] [Reference Citation Analysis]
515 Hajifathali A, Parkhideh S, Kazemi MH, Chegeni R, Roshandel E, Gholizadeh M. Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted! J Cell Physiol 2020;235:9080-97. [DOI: 10.1002/jcp.29769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
516 Lu C, Liu K. Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy. Transl Cancer Res 2017;6:S652-4. [PMID: 30613482 DOI: 10.21037/tcr.2017.05.32] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
517 Wang F, Lu JB, Wu XY, Feng YF, Shao Q, An X, Wang HY. Clinical genetic features and related survival implications in patients with surgically resected large-cell lung cancer. Cancer Manag Res 2019;11:5489-99. [PMID: 31354355 DOI: 10.2147/CMAR.S200263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
518 Zhang M, Yang J, Zhou J, Gao W, Zhang Y, Lin Y, Wang H, Ruan Z, Ni B. Prognostic Values of CD38 + CD101 + PD1 + CD8 + T Cells in Pancreatic Cancer. Immunological Investigations 2019;48:466-79. [DOI: 10.1080/08820139.2019.1566356] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
519 Hofman P. PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted? Expert Rev Mol Diagn 2017;17:1097-108. [PMID: 29069958 DOI: 10.1080/14737159.2017.1398083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
520 Alldredge J, Serna-Gallegos T, Gallegos N, VanLeer JP, Chang J, Ziogas A, Goreal W, Randall L. Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival. Gynecol Oncol 2019;155:483-8. [PMID: 31653509 DOI: 10.1016/j.ygyno.2019.10.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
521 He Y, Zhang X, Jia K, Dziadziuszko R, Zhao S, Deng J, Wang H, Hirsch FR, Zhou C. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Transl Lung Cancer Res 2019;8:352-66. [PMID: 31555511 DOI: 10.21037/tlcr.2019.08.15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
522 Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S, Orlandi F, Sanborn RE, Szalai Z, Ursol G, Mendus D, Wang L, Wen X, McCleland M, Hoang T, Phan S, Socinski MA. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. J Thorac Oncol 2021;16:653-64. [PMID: 33333328 DOI: 10.1016/j.jtho.2020.11.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
523 Huang X, Tang T, Zhang G, Hong Z, Xu J, Yadav DK, Bai X, Liang T. Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. NPJ Precis Oncol 2020;4:29. [PMID: 33299118 DOI: 10.1038/s41698-020-00136-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
524 Acharya AP, Sinha M, Ratay ML, Ding X, Balmert SC, Workman CJ, Wang Y, Vignali DAA, Little SR. Localized Multi-Component Delivery Platform Generates Local and Systemic Anti-Tumor Immunity. Adv Funct Mater 2017;27:1604366. [DOI: 10.1002/adfm.201604366] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
525 Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, Deguchi T, Kato Y, Yamamoto S, Yamamoto K, Toda M, Nakajima C, Suzuki Y, Murata S, Ohashi K. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol 2021;5:10. [PMID: 33580183 DOI: 10.1038/s41698-021-00147-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
526 Meyers DE, Bryan PM, Banerji S, Morris DG. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. Curr Oncol 2018;25:e324-34. [PMID: 30111979 DOI: 10.3747/co.25.3976] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
527 Han X, Wang L, Li T, Zhang J, Zhang D, Li J, Xia Y, Liu Y, Tan W. Beyond Blocking: Engineering RNAi-Mediated Targeted Immune Checkpoint Nanoblocker Enables T-Cell-Independent Cancer Treatment. ACS Nano 2020. [PMID: 33290659 DOI: 10.1021/acsnano.0c08022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
528 Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? Clin Lung Cancer. 2016; Epub ahead of print. [PMID: 27137346 DOI: 10.1016/j.cllc.2016.03.011] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 11.5] [Reference Citation Analysis]
529 Nishio M, Sugawara S, Atagi S, Akamatsu H, Sakai H, Okamoto I, Takayama K, Hayashi H, Nakagawa Y, Kawakami T. Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). Clin Lung Cancer 2019;20:469-476.e1. [PMID: 31466854 DOI: 10.1016/j.cllc.2019.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
530 Peters S, Galle PR, Bernaards CA, Ballinger M, Bruno R, Quarmby V, Ruppel J, Vilimovskij A, Wu B, Sternheim N, Reck M. Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). Clin Transl Sci 2021. [PMID: 34582105 DOI: 10.1111/cts.13149] [Reference Citation Analysis]
531 Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. J Natl Cancer Inst 2019;111:118-28. [PMID: 30561713 DOI: 10.1093/jnci/djy196] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
532 Toyokawa G, Takada K, Okamoto T, Kawanami S, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Katsura M, Yamada Y, Shoji F, Baba S, Kamitani T, Oda Y, Honda H, Maehara Y. Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. Ann Thorac Surg 2017;103:1750-7. [PMID: 28347537 DOI: 10.1016/j.athoracsur.2016.12.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
533 Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood) 2015;240:1087-98. [PMID: 25956686 DOI: 10.1177/1535370215584936] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
534 Ma Z, Wang F, Zhong Y, Salazar F, Li J, Zhang M, Ren F, Wu AM, Dai H. Cross-Link-Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications. Angew Chem Weinheim Bergstr Ger 2020;132:20733-41. [PMID: 34334834 DOI: 10.1002/ange.202008083] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
535 Kato K, Doki Y, Ura T, Hamamoto Y, Kojima T, Tsushima T, Hironaka S, Hara H, Kudo T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Kitagawa Y. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer Sci 2020;111:1676-84. [PMID: 32160365 DOI: 10.1111/cas.14380] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
536 McLean AEB, Barnes DJ, Troy LK. Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine. J Clin Med. 2018;7:163. [PMID: 29966246 DOI: 10.3390/jcm7070163] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
537 Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Zhao H, Zhang L. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016;6:20090. [PMID: 26822379 DOI: 10.1038/srep20090] [Cited by in Crossref: 95] [Cited by in F6Publishing: 106] [Article Influence: 15.8] [Reference Citation Analysis]
538 Wang HC, Hung WC, Chen LT, Pan MR. From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. Int J Mol Sci 2018;19:E3584. [PMID: 30428588 DOI: 10.3390/ijms19113584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
539 Kartikasari AER, Prakash MD, Cox M, Wilson K, Boer JC, Cauchi JA, Plebanski M. Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation. Front Immunol 2018;9:3109. [PMID: 30740111 DOI: 10.3389/fimmu.2018.03109] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
540 Abdolahi S, Ghazvinian Z, Muhammadnejad S, Ahmadvand M, Aghdaei HA, Ebrahimi-Barough S, Ai J, Zali MR, Verdi J, Baghaei K. Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model. Front Pharmacol 2021;12:733075. [PMID: 34588986 DOI: 10.3389/fphar.2021.733075] [Reference Citation Analysis]
541 Tunger A, Kießler M, Wehner R, Temme A, Meier F, Bachmann M, Schmitz M. Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines 2018;6:E26. [PMID: 29494517 DOI: 10.3390/biomedicines6010026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
542 Mu L, Yu W, Su H, Lin Y, Sui W, Yu X, Qin C. Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer. Artif Cells Nanomed Biotechnol 2019;47:1036-42. [PMID: 30983436 DOI: 10.1080/21691401.2019.1573741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
543 Nguyen A, Ramesh A, Kumar S, Nandi D, Brouillard A, Wells A, Pobezinsky L, Osborne B, Kulkarni AA. Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy. Sci Adv 2020;6:eabc2777. [PMID: 33008894 DOI: 10.1126/sciadv.abc2777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
544 Theelen WSME, Krijgsman O, Monkhorst K, Kuilman T, Peters DDGC, Cornelissen S, Ligtenberg MA, Willems SM, Blaauwgeers JLG, van Noesel CJM, Peeper DS, van den Heuvel MM, Schulze K. Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma. J Transl Med 2020;18:271. [PMID: 32620126 DOI: 10.1186/s12967-020-02436-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
545 Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature 2017;541:321-30. [DOI: 10.1038/nature21349] [Reference Citation Analysis]
546 Manzo A, Carillio G, Montanino A, Sforza V, Palumbo G, Esposito G, Costanzo R, Sandomenico C, La Manna C, Martucci N, La Rocca A, De Luca G, Piccirillo MC, De Cecio R, Botti G, Totaro G, Muto P, Picone C, Normanno N, Morabito A. The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. Expert Opin Drug Saf 2020;19:775-83. [PMID: 32400223 DOI: 10.1080/14740338.2020.1767584] [Reference Citation Analysis]
547 Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 2015;6:26483-93. [PMID: 26317899 DOI: 10.18632/oncotarget.4494] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 14.7] [Reference Citation Analysis]
548 Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 2016;7:13587-98. [PMID: 26871470 DOI: 10.18632/oncotarget.7277] [Cited by in Crossref: 293] [Cited by in F6Publishing: 289] [Article Influence: 58.6] [Reference Citation Analysis]
549 Nsingwane Z, Candy G, Devar J, Omoshoro-Jones J, Smith M, Nweke E. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects. Mol Biol Rep 2020;47:6269-80. [PMID: 32661873 DOI: 10.1007/s11033-020-05648-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
550 Lloyd IE, Zhou W, Witt BL, Chadwick BE. Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods. Applied Immunohistochemistry & Molecular Morphology 2019;27:107-13. [DOI: 10.1097/pai.0000000000000572] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 6.7] [Reference Citation Analysis]
551 Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 2021;11:5365-86. [PMID: 33859752 DOI: 10.7150/thno.58390] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
552 Tibaldi C, Lunghi A, Baldini E. Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World J Clin Oncol 2017; 8(4): 320-328 [PMID: 28848698 DOI: 10.5306/wjco.v8.i4.320] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
553 Gammelgaard OL, Terp MG, Preiss B, Ditzel HJ. Human cancer evolution in the context of a human immune system in mice. Mol Oncol 2018;12:1797-810. [PMID: 30120895 DOI: 10.1002/1878-0261.12374] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
554 Peranzoni E, Donnadieu E. [Improving efficacy of cancer immunotherapy through targeting of macrophages]. Med Sci (Paris) 2019;35:207-9. [PMID: 30931902 DOI: 10.1051/medsci/2019043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
555 Matsuda A, Ishiguro K, Yan IK, Patel T. Extracellular Vesicle-Based Therapeutic Targeting of β-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer. Hepatol Commun 2019;3:525-41. [PMID: 30976743 DOI: 10.1002/hep4.1311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
556 Lin YT, Jeng LB, Chan WL, Su IJ, Teng CF. Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma. Viruses 2021;13:862. [PMID: 34066744 DOI: 10.3390/v13050862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
557 Panigrahi S, Bazdar DA, Albakri M, Ferrari B, Antonelli CJ, Freeman ML, Dubyak G, Zender C, Sieg SF. CD8+ CD73+ T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue. Eur J Immunol 2020;50:2055-66. [PMID: 32548862 DOI: 10.1002/eji.202048626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
558 Cheng CC, Lin HC, Tsai KJ, Chiang YW, Lim KH, Chen CG, Su YW, Peng CL, Ho AS, Huang L, Chang YC, Lin HC, Chang J, Chang YF. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers. Mol Carcinog 2018;57:1588-98. [PMID: 30035369 DOI: 10.1002/mc.22881] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
559 Facchinetti F, Bordi P, Leonetti A, Buti S, Tiseo M. Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Drug Des Devel Ther 2018;12:2857-73. [PMID: 30237696 DOI: 10.2147/DDDT.S124380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
560 Hude I, Sasse S, Engert A, Bröckelmann PJ. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica 2017;102:30-42. [PMID: 27884973 DOI: 10.3324/haematol.2016.150656] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
561 Chen T, Xu XY, Zhou PH. Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer. 2016;35:49. [PMID: 27233623 DOI: 10.1186/s40880-016-0111-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
562 Mima K, Ogino S, Nakagawa S, Sawayama H, Kinoshita K, Krashima R, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Sakamoto Y, Yamashita YI, Yoshida N, Chikamoto A, Ishiko T, Baba H. The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surg Oncol 2017;26:368-76. [PMID: 29113654 DOI: 10.1016/j.suronc.2017.07.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
563 Lee SW, Lee HY, Kang SW, Kim MJ, Lee YJ, Sung CO, Kim YM. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer. Int J Mol Sci 2021;22:9638. [PMID: 34502561 DOI: 10.3390/ijms22179638] [Reference Citation Analysis]
564 Wang YN, Lee HH, Hsu JL, Yu D, Hung MC. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci 2020;27:77. [PMID: 32620165 DOI: 10.1186/s12929-020-00670-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
565 Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28:874-881. [PMID: 28168303 DOI: 10.1093/annonc/mdx008] [Cited by in Crossref: 130] [Cited by in F6Publishing: 129] [Article Influence: 26.0] [Reference Citation Analysis]
566 Bae J, Accardi F, Hideshima T, Tai YT, Prabhala R, Shambley A, Wen K, Rowell S, Richardson PG, Munshi NC, Anderson KC. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia 2021. [PMID: 34290359 DOI: 10.1038/s41375-021-01301-6] [Reference Citation Analysis]
567 Hofer F, Di Sario G, Musiu C, Sartoris S, De Sanctis F, Ugel S. A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. Cells 2021;10:2700. [PMID: 34685679 DOI: 10.3390/cells10102700] [Reference Citation Analysis]
568 Miranda-Galvis M, Rumayor Piña A, Sales de Sá R, Almeida Leite A, Agustin Vargas P, Calsavara VF, Lópes Pinto CA, Teng Y, Kowalski LP. PD-L1 expression patterns in oral cancer as an integrated approach for further prognostic classification. Oral Dis 2020. [PMID: 33169454 DOI: 10.1111/odi.13714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
569 Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, Neesse A. Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews 2020;100:1707-51. [DOI: 10.1152/physrev.00042.2019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
570 He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, Zhou C, Hirsch FR. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci. 2016;107:1193-1197. [PMID: 27297395 DOI: 10.1111/cas.12986] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 14.2] [Reference Citation Analysis]
571 Apolo AB. PDL1: The Illusion of an Ideal Biomarker. Eur Urol Focus 2016;1:269-71. [PMID: 28723398 DOI: 10.1016/j.euf.2015.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
572 Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol 2021:S0923-7534(21)04824-9. [PMID: 34843940 DOI: 10.1016/j.annonc.2021.11.009] [Reference Citation Analysis]
573 Bauer C, Kühnemuth B, Duewell P, Ormanns S, Gress T, Schnurr M. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Letters 2016;381:259-68. [DOI: 10.1016/j.canlet.2016.02.057] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
574 Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016;21:821-833. [PMID: 27101251 DOI: 10.1111/resp.12789] [Cited by in Crossref: 66] [Cited by in F6Publishing: 75] [Article Influence: 11.0] [Reference Citation Analysis]
575 Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, Huang M, Vlad AM, Lu B, Oesterreich S, Davidson NE, Huang Y. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene 2019;38:390-405. [PMID: 30111819 DOI: 10.1038/s41388-018-0451-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
576 Stühler V, Maas JM, Rausch S, Stenzl A, Bedke J. Immune checkpoint inhibition for the treatment of renal cell carcinoma. Expert Opin Biol Ther 2020;20:83-94. [PMID: 31587590 DOI: 10.1080/14712598.2020.1677601] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
577 Zhang J, Quadri S, Wolfgang CL, Zheng L. New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines 2018;6:E87. [PMID: 30104497 DOI: 10.3390/biomedicines6030087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
578 Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest 2018;128:4441-53. [PMID: 30179225 DOI: 10.1172/JCI121924] [Cited by in Crossref: 67] [Cited by in F6Publishing: 29] [Article Influence: 16.8] [Reference Citation Analysis]
579 Deng H, Zhang Z. The application of nanotechnology in immune checkpoint blockade for cancer treatment. J Control Release 2018;290:28-45. [PMID: 30287266 DOI: 10.1016/j.jconrel.2018.09.026] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
580 Sudo K, Yamada Y. Advancing pharmacological treatment options for advanced gastric cancer. Expert Opin Pharmacother 2015;16:2293-305. [PMID: 26359224 DOI: 10.1517/14656566.2015.1080238] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
581 Andersen R, Borch T, Draghi A, Gokuldass A, Rana M, Pedersen M, Nielsen M, Kongsted P, Kjeldsen J, Westergaard M, Radic H, Chamberlain C, Hölmich L, Hendel H, Larsen M, Met Ö, Svane I, Donia M. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Annals of Oncology 2018;29:1575-81. [DOI: 10.1093/annonc/mdy139] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
582 Nagaya T, Nakamura Y, Sato K, Harada T, Choyke PL, Hodge JW, Schlom J, Kobayashi H. Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget. 2017;8:8807-8817. [PMID: 27716622 DOI: 10.18632/oncotarget.12410] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
583 Greenplate AR, Johnson DB, Roussel M, Savona MR, Sosman JA, Puzanov I, Ferrell PB, Irish JM. Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. Cancer Immunol Res 2016;4:474-80. [PMID: 26966176 DOI: 10.1158/2326-6066.CIR-15-0213] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
584 Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging 2017;44:2310-25. [PMID: 28815334 DOI: 10.1007/s00259-017-3802-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
585 Chen Y, Wang L, Zheng M, Zhu C, Wang G, Xia Y, Blumenthal EJ, Mao W, Wan Y. Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy. Bioact Mater 2022;9:251-65. [PMID: 34820569 DOI: 10.1016/j.bioactmat.2021.07.012] [Reference Citation Analysis]
586 Mayer AT, Natarajan A, Gordon SR, Maute RL, McCracken MN, Ring AM, Weissman IL, Gambhir SS. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. J Nucl Med 2017;58:538-46. [PMID: 27980047 DOI: 10.2967/jnumed.116.177659] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
587 Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, Jost C, Fransen MF, Buser RB, Kowanetz M, Rommel K, Matos I, Colombetti S, Belousov A, Karanikas V, Ossendorp F, Hegde PS, Chen DS, Umana P, Perro M, Klein C, Xu W. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med 2020;12:eaav7431. [PMID: 32161104 DOI: 10.1126/scitranslmed.aav7431] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 83.0] [Reference Citation Analysis]
588 Koganemaru S, Inoshita N, Miura Y, Miyama Y, Fukui Y, Ozaki Y, Tomizawa K, Hanaoka Y, Toda S, Suyama K, Tanabe Y, Moriyama J, Fujii T, Matoba S, Kuroyanagi H, Takano T. Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. Cancer Sci 2017;108:853-8. [PMID: 28267224 DOI: 10.1111/cas.13229] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
589 Wei R, Guo L, Wang Q, Miao J, Kwok HF, Lin Y. Targeting PD-L1 Protein: Translation, Modification and Transport. CPPS 2018;20:82-91. [DOI: 10.2174/1389203719666180928105632] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
590 Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, Boellaard R, Du S, Hayes W, Smith R, Windhorst AD, Hendrikse NH, Poot A, Vugts DJ, Thunnissen E, Morin P, Lipovsek D, Donnelly DJ, Bonacorsi SJ, Velasquez LM, de Gruijl TD, Smit EF, de Langen AJ. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun 2018;9:4664. [PMID: 30405135 DOI: 10.1038/s41467-018-07131-y] [Cited by in Crossref: 145] [Cited by in F6Publishing: 132] [Article Influence: 36.3] [Reference Citation Analysis]
591 Song Z, Yu X, Cheng G, Zhang Y. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. J Transl Med 2016;14:188. [PMID: 27342566 DOI: 10.1186/s12967-016-0943-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
592 Schreiber LM, Urbiola C, Das K, Spiesschaert B, Kimpel J, Heinemann F, Stierstorfer B, Müller P, Petersson M, Erlmann P, von Laer D, Wollmann G. The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer. Br J Cancer 2019;121:647-58. [PMID: 31530903 DOI: 10.1038/s41416-019-0574-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
593 Qiu L, Tan H, Lin Q, Si Z, Mao W, Wang T, Fu Z, Cheng D, Shi H. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry. Mol Imaging Biol 2020;22:842-53. [PMID: 31741201 DOI: 10.1007/s11307-019-01441-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
594 Gandhi L, Vansteenkiste JF, Shepherd FA. Immunotherapy and Lung Cancer. IASLC Thoracic Oncology. Elsevier; 2018. pp. 501-511.e3. [DOI: 10.1016/b978-0-323-52357-8.00050-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
595 Tokito T, Azuma K, Kawahara A, Ishii H, Yamada K, Matsuo N, Kinoshita T, Mizukami N, Ono H, Kage M, Hoshino T. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer 2016;55:7-14. [PMID: 26771872 DOI: 10.1016/j.ejca.2015.11.020] [Cited by in Crossref: 103] [Cited by in F6Publishing: 110] [Article Influence: 17.2] [Reference Citation Analysis]
596 Chen H, Zhang X, Zhang T, Li X, Li J, Yue Y, Wang M, Zheng Y, Fan H, Wang J, Yao M. Ambient PM Toxicity Is Correlated with Expression Levels of Specific MicroRNAs. Environ Sci Technol 2020;54:10227-36. [DOI: 10.1021/acs.est.0c03876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
597 Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. J Clin Invest 2019;129:616-30. [PMID: 30457978 DOI: 10.1172/JCI122216] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 12.7] [Reference Citation Analysis]
598 Ukleja J, Kusaka E, Miyamoto DT. Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies. Front Oncol 2021;11:663852. [PMID: 34041029 DOI: 10.3389/fonc.2021.663852] [Reference Citation Analysis]
599 Paluch BE, Glenn ST, Conroy JM, Papanicolau-Sengos A, Bshara W, Omilian AR, Brese E, Nesline M, Burgher B, Andreas J, Odunsi K, Eng K, He J, Qin M, Gardner M, Galluzzi L, Morrison CD. Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget 2017;8:3197-205. [PMID: 27911273 DOI: 10.18632/oncotarget.13691] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
600 Ma J. Bioinformatics-guided analysis uncovers TIGIT as an epigenetically regulated immunomodulator affecting immunotherapeutic sensitivity of gastric cancer. Cancer Biomark 2021. [PMID: 34511485 DOI: 10.3233/CBM-210159] [Reference Citation Analysis]
601 Gong K, Gong ZJ, Lu PX, Ni XL, Shen S, Liu H, Wang JW, Zhang DX, Liu HB, Suo T. PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma. Biochem Biophys Res Commun 2019;516:983-90. [PMID: 31272718 DOI: 10.1016/j.bbrc.2019.06.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
602 Kim J, Kong JK, Yang W, Cho H, Chay DB, Lee BH, Cho SJ, Hong S, Kim JH. DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer. Cancers (Basel) 2018;10:E279. [PMID: 30134578 DOI: 10.3390/cancers10090279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
603 Bhalla S, Doroshow DB, Hirsch FR. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions. Cancer J 2020;26:507-16. [PMID: 33298722 DOI: 10.1097/PPO.0000000000000483] [Reference Citation Analysis]
604 Mao L, Tang Y, Deng MJ, Huang CT, Lan D, Nong WZ, Li L, Wang Q. A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer. J Clin Lab Anal 2022;:e24232. [PMID: 34995016 DOI: 10.1002/jcla.24232] [Reference Citation Analysis]
605 Sakane T, Murase T, Okuda K, Takino H, Masaki A, Oda R, Watanabe T, Kawano O, Haneda H, Moriyama S, Saito Y, Yamada T, Nakanishi R, Inagaki H. A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. Oncotarget 2018;9:6993-7009. [PMID: 29467945 DOI: 10.18632/oncotarget.24075] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
606 Shen H, Sun T, Hoang HH, Burchfield JS, Hamilton GF, Mittendorf EA, Ferrari M. Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Semin Immunol 2017;34:114-22. [PMID: 28947107 DOI: 10.1016/j.smim.2017.09.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
607 Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016;21:462-73. [DOI: 10.1007/s10147-016-0959-z] [Reference Citation Analysis]
608 Lin A, Zhang H, Meng H, Deng Z, Gu T, Luo P, Zhang J. TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Front Immunol 2021;12:667875. [PMID: 34603277 DOI: 10.3389/fimmu.2021.667875] [Reference Citation Analysis]
609 Soyano AE, Dholaria B, Marin-Acevedo JA, Diehl N, Hodge D, Luo Y, Manochakian R, Chumsri S, Adjei A, Knutson KL, Lou Y. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer 2018;6:129. [PMID: 30470260 DOI: 10.1186/s40425-018-0447-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
610 Gubin MM, Schreiber RD. CANCER. The odds of immunotherapy success. Science 2015;350:158-9. [PMID: 26450194 DOI: 10.1126/science.aad4140] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 9.4] [Reference Citation Analysis]
611 Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O’hear C, Lai C, Hu S, Ballinger M, Sandler A, Gandhi M, Fehrenbacher L. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer 2019;128:105-12. [DOI: 10.1016/j.lungcan.2018.12.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 15.7] [Reference Citation Analysis]
612 Sughayer MA, Alnaimy F, Alsughayer AM, Qamhia N. Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC. Applied Immunohistochemistry & Molecular Morphology 2019;27:663-6. [DOI: 10.1097/pai.0000000000000671] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
613 Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O'Hear C, Lin YG, Emens LA. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol 2019;154:314-22. [PMID: 31204078 DOI: 10.1016/j.ygyno.2019.05.021] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
614 Chen TL, Patel AS, Jain V, Kuppusamy R, Lin YW, Hou MH, Su TL, Lee TC. Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[g]pyrrolo[2,1-a]phthalazine Hybrids That Inhibit Angiogenesis and Induce DNA Cross-Links. J Med Chem 2021;64:12469-86. [PMID: 34459195 DOI: 10.1021/acs.jmedchem.0c01733] [Reference Citation Analysis]
615 Cummings CA, Peters E, Lacroix L, Andre F, Lackner MR. The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. Clin Transl Sci 2016;9:283-92. [PMID: 27860319 DOI: 10.1111/cts.12429] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
616 Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015;12:511-26. [PMID: 25963091 DOI: 10.1038/nrclinonc.2015.90] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 22.1] [Reference Citation Analysis]
617 Noh B, Hong S, Jun S, Eom D. Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma. Pathology 2020;52:228-35. [DOI: 10.1016/j.pathol.2019.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
618 Voorwerk L, Kat M, Kok M. Towards predictive biomarkers for immunotherapy response in breast cancer patients. Breast Cancer Management 2018;7:BMT05. [DOI: 10.2217/bmt-2017-0014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
619 Chiossone L, Vienne M, Kerdiles YM, Vivier E. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more. Seminars in Immunology 2017;31:55-63. [DOI: 10.1016/j.smim.2017.08.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 13.8] [Reference Citation Analysis]
620 Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? World J Gastroenterol 2018; 24(20): 2137-2151 [PMID: 29853732 DOI: 10.3748/wjg.v24.i20.2137] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 54] [Article Influence: 15.8] [Reference Citation Analysis]
621 Xu PP, Sun C, Cao X, Zhao X, Dai HJ, Lu S, Guo JJ, Fu SJ, Liu YX, Li SC, Chen M, McCord R, Venstrom J, Szafer-Glusman E, Punnoose E, Kiermaier A, Cheng G, Zhao WL. Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies. EBioMedicine 2018;33:94-104. [PMID: 29936139 DOI: 10.1016/j.ebiom.2018.06.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
622 Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, Marone G, Tocchetti CG. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2017;2:e000247. [PMID: 29104763 DOI: 10.1136/esmoopen-2017-000247] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 19.6] [Reference Citation Analysis]
623 Lee SJ, Jun SY, Lee IH, Kang BW, Park SY, Kim HJ, Park JS, Choi GS, Yoon G, Kim JG. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. J Cancer Res Clin Oncol 2018;144:1005-14. [PMID: 29520442 DOI: 10.1007/s00432-018-2620-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
624 Segal NH, Ou SI, Balmanoukian A, Fury MG, Massarelli E, Brahmer JR, Weiss J, Schöffski P, Antonia SJ, Massard C, Zandberg DP, Khleif SN, Xiao F, Rebelatto MC, Steele KE, Robbins PB, Angra N, Song X, Abdullah S, Butler M. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. Eur J Cancer 2019;109:154-61. [PMID: 30731276 DOI: 10.1016/j.ejca.2018.12.029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
625 Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, Fassò M, Osborne S, Molinero L, O’hear C, Grossman W, Baehring J. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol 2018;140:317-28. [DOI: 10.1007/s11060-018-2955-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
626 Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C. Novel immunotherapy in the treatment of advanced non-small cell lung cancer. Expert Review of Clinical Pharmacology 2016;9:1571-81. [DOI: 10.1080/17512433.2016.1236681] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
627 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509-2520. [PMID: 26028255 DOI: 10.1056/nejmoa1500596] [Cited by in Crossref: 4650] [Cited by in F6Publishing: 2768] [Article Influence: 664.3] [Reference Citation Analysis]
628 Nixon NA, Blais N, Ernst S, Kollmannsberger C, Bebb G, Butler M, Smylie M, Verma S. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol 2018;25:e373-84. [PMID: 30464687 DOI: 10.3747/co.25.3840] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
629 Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 2017;9:eaah3560. [PMID: 28251903 DOI: 10.1126/scitranslmed.aah3560] [Cited by in Crossref: 318] [Cited by in F6Publishing: 282] [Article Influence: 63.6] [Reference Citation Analysis]
630 Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, Capone M. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med 2016;14:273. [PMID: 27650038 DOI: 10.1186/s12967-016-1029-z] [Cited by in Crossref: 95] [Cited by in F6Publishing: 95] [Article Influence: 15.8] [Reference Citation Analysis]
631 Ren J, Xu M, Chen J, Ding J, Wang P, Huo L, Li F, Liu Z. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled αPD-L1 antibody. Theranostics 2021;11:304-15. [PMID: 33391476 DOI: 10.7150/thno.45540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
632 Kang X, Chen K, Li Y, Li J, D'Amico TA, Chen X. Personalized targeted therapy for esophageal squamous cell carcinoma. World J Gastroenterol 2015; 21(25): 7648-7658 [PMID: 26167067 DOI: 10.3748/wjg.v21.i25.7648] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
633 Callahan MK, Postow MA, Wolchok JD. Targeting T Cell Co-receptors for Cancer Therapy. Immunity 2016;44:1069-78. [PMID: 27192570 DOI: 10.1016/j.immuni.2016.04.023] [Cited by in Crossref: 271] [Cited by in F6Publishing: 261] [Article Influence: 54.2] [Reference Citation Analysis]
634 Jürets A, Le Bras M, Staffler G, Stein G, Leitner L, Neuhofer A, Tardelli M, Turkof E, Zeyda M, Stulnig TM. Inhibition of Cellular Adhesion by Immunological Targeting of Osteopontin Neoepitopes Generated through Matrix Metalloproteinase and Thrombin Cleavage. PLoS One 2016;11:e0148333. [PMID: 26840958 DOI: 10.1371/journal.pone.0148333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
635 Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS, Christensen JG. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol Immunother 2018;67:381-92. [PMID: 29124315 DOI: 10.1007/s00262-017-2091-y] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 10.8] [Reference Citation Analysis]
636 Chang H, Liu B, Qi Y, Zhou Y, Chen Y, Pan K, Li W, Zhou X, Ma W, Fu C, Qi Y, Liu L, Gao Y. Blocking of the PD‐1/PD‐L1 Interaction by a D ‐Peptide Antagonist for Cancer Immunotherapy. Angew Chem Int Ed 2015;54:11760-4. [DOI: 10.1002/anie.201506225] [Cited by in Crossref: 140] [Cited by in F6Publishing: 131] [Article Influence: 20.0] [Reference Citation Analysis]
637 Dietrich B, Siefker-radtke AO, Srinivas S, Yu EY. Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_201193] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
638 Narang P, Chen M, Sharma AA, Anderson KS, Wilson MA. The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer. 2019;19:200. [PMID: 30832597 DOI: 10.1186/s12885-019-5402-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
639 Lan X, Zhu W, Huang X, Yu Y, Xiao H, Jin L, Pu JJ, Xie X, She J, Lui VWY, Chen H, Su Y. Microneedles loaded with anti-PD-1–cisplatin nanoparticles for synergistic cancer immuno-chemotherapy. Nanoscale 2020;12:18885-98. [DOI: 10.1039/d0nr04213g] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
640 Yeong J, Thike AA, Lim JCT, Lee B, Li H, Wong S, Hue SSS, Tan PH, Iqbal J. Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Res Treat 2017;163:21-35. [DOI: 10.1007/s10549-017-4161-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
641 Xie Y, Olkhov-Mitsel E, Alminawi S, Slodkowska E, Downes MR. Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma. Pathol Res Pract 2021;226:153607. [PMID: 34509050 DOI: 10.1016/j.prp.2021.153607] [Reference Citation Analysis]
642 Ragonnaud E, Andersson AM, Pedersen AE, Laursen H, Holst PJ. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression. Vaccine 2016;34:2147-56. [PMID: 27004934 DOI: 10.1016/j.vaccine.2015.06.087] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
643 Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462-472. [PMID: 25858805 DOI: 10.1016/j.ccell.2015.02.015] [Cited by in Crossref: 647] [Cited by in F6Publishing: 621] [Article Influence: 92.4] [Reference Citation Analysis]
644 Huang J, Zhang D, Bai Y, Yang P, Xing L, Yu J. A2AR Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. J Cancer 2020;11:3685-92. [PMID: 32284765 DOI: 10.7150/jca.43966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
645 Lehtipuro S, Nykter M, Granberg KJ. Modes of immunosuppression in glioblastoma microenvironment. Oncotarget 2019;10:920-1. [PMID: 30847018 DOI: 10.18632/oncotarget.26643] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
646 Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser C, Fassò M, O'Hear C, Vogelzang NJ. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. JAMA Oncol 2018;4:537-44. [PMID: 29423515 DOI: 10.1001/jamaoncol.2017.5440] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 20.7] [Reference Citation Analysis]
647 Singh PP, Sharma PK, Krishnan G, Lockhart AC. Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf). 2015;3:289-297. [PMID: 26510455 DOI: 10.1093/gastro/gov053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
648 Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, Kim BYS, Story MD, Jiang W. The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clin Cancer Res 2019;25:1709-17. [PMID: 30413527 DOI: 10.1158/1078-0432.CCR-18-2581] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 6.8] [Reference Citation Analysis]
649 Zhao T, Li C, Wu Y, Li B, Zhang B. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. PLoS One. 2017;12:e0176822. [PMID: 28453554 DOI: 10.1371/journal.pone.0176822] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
650 Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265-276. [PMID: 25797516 DOI: 10.1016/j.it.2015.02.008] [Cited by in Crossref: 517] [Cited by in F6Publishing: 493] [Article Influence: 73.9] [Reference Citation Analysis]
651 He J, Ouyang W, Zhao W, Shao L, Li B, Liu B, Wang D, Han-Zhang H, Zhang Z, Shao L, Li W. Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor. Ann Transl Med 2021;9:129. [PMID: 33569431 DOI: 10.21037/atm-20-7553] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
652 Errico A. Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer. Nat Rev Clin Oncol 2015;12:63. [PMID: 25533942 DOI: 10.1038/nrclinonc.2014.221] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
653 Zha H, Jiang Y, Wang X, Shang J, Wang N, Yu L, Zhao W, Li Z, An J, Zhang X, Chen H, Zhu B, Li Z. Non-canonical PD-1 signaling in cancer and its potential implications in clinic. J Immunother Cancer 2021;9:e001230. [PMID: 33593825 DOI: 10.1136/jitc-2020-001230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
654 He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 2018;149:253-61. [PMID: 29425258 DOI: 10.1093/ajcp/aqx162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
655 Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology 2018;7:e1509819. [PMID: 30377572 DOI: 10.1080/2162402X.2018.1509819] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
656 Sanseviero E. NK Cell-Fc Receptors Advance Tumor Immunotherapy. J Clin Med 2019;8:E1667. [PMID: 31614774 DOI: 10.3390/jcm8101667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
657 Phan TG, Long GV, Scolyer RA. Multiple checkpoints on the long road towards cancer immunotherapy. Immunol Cell Biol 2015;93:323-5. [DOI: 10.1038/icb.2015.12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
658 Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. [PMID: 28018338 DOI: 10.3389/fimmu.2016.00550] [Cited by in Crossref: 219] [Cited by in F6Publishing: 226] [Article Influence: 36.5] [Reference Citation Analysis]
659 Vrankar M, Stanic K. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiol Oncol 2018;52:281-8. [PMID: 30210037 DOI: 10.2478/raon-2018-0009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
660 Shibru B, Fey K, Fricke S, Blaudszun AR, Fürst F, Weise M, Seiffert S, Weyh MK, Köhl U, Sack U, Boldt A. Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry. Front Immunol 2021;12:694055. [PMID: 34276685 DOI: 10.3389/fimmu.2021.694055] [Reference Citation Analysis]
661 Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol 2020;25:790-800. [PMID: 31900651 DOI: 10.1007/s10147-019-01588-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 22.0] [Reference Citation Analysis]
662 Nilsson JS, Sobti A, Swoboda S, Erjefält JS, Forslund O, Lindstedt M, Greiff L. Immune Phenotypes of Nasopharyngeal Cancer. Cancers (Basel) 2020;12:E3428. [PMID: 33218184 DOI: 10.3390/cancers12113428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
663 Davarpanah NN, Yuno A, Trepel JB, Apolo AB. Immunotherapy: a new treatment paradigm in bladder cancer. Curr Opin Oncol 2017;29:184-95. [PMID: 28306559 DOI: 10.1097/CCO.0000000000000366] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
664 Leduc C, Adam J, Louvet E, Sourisseau T, Dorvault N, Bernard M, Maingot E, Faivre L, Cassin-Kuo MS, Boissier E, Dessoliers MC, Robin A, Casiraghi O, Even C, Temam S, Olaussen KA, Soria JC, Postel-Vinay S. TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open 2018;3:e000257. [PMID: 29344407 DOI: 10.1136/esmoopen-2017-000257] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
665 Galluzzi L, Rudqvist NP. Preface: More than two decades of modern tumor immunology. Methods Enzymol 2020;631:xxiii-xlii. [PMID: 31948570 DOI: 10.1016/S0076-6879(20)30020-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
666 Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267-1284. [PMID: 30275043 DOI: 10.1101/gad.314617.118] [Cited by in Crossref: 419] [Cited by in F6Publishing: 401] [Article Influence: 104.8] [Reference Citation Analysis]
667 Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu Y, Tu S, Li Y. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Front Immunol 2019;10:2664. [PMID: 31798590 DOI: 10.3389/fimmu.2019.02664] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 22.7] [Reference Citation Analysis]
668 Peranzoni E, Donnadieu E. Improving efficacy of cancer immunotherapy through targeting of macrophages. Hum Vaccin Immunother 2019;15:189-92. [PMID: 30192699 DOI: 10.1080/21645515.2018.1515447] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
669 Zhang Y, Li Z, Chen Y, Tan L, Zeng Z, Ding J, Du S. Induction Strategy for Locally Advanced Thymoma. Front Oncol 2021;11:704220. [PMID: 34367988 DOI: 10.3389/fonc.2021.704220] [Reference Citation Analysis]
670 Yun S, Park Y, Moon S, Ahn S, Lee K, Park HJ, Lee HS, Choe G, Lee KS. Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. J Cancer 2019;10:3070-8. [PMID: 31281485 DOI: 10.7150/jca.30573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
671 Long L, Chen M, Yuan Y, Ming AL, Guo W, Wu K, Chen H. High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma. J Cancer 2020;11:4442-52. [PMID: 32489463 DOI: 10.7150/jca.42610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
672 Xu G, Sun L, Li Y, Xie F, Zhou X, Yang H, Du S, Xu H, Mao Y. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Front Oncol 2019;9:897. [PMID: 31620360 DOI: 10.3389/fonc.2019.00897] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
673 Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res 2017;23:4270-9. [PMID: 28223273 DOI: 10.1158/1078-0432.CCR-16-3146] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 15.4] [Reference Citation Analysis]
674 Brouwer TP, Vahrmeijer AL, de Miranda NFCC. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cell Oncol (Dordr) 2021;44:261-78. [PMID: 33710604 DOI: 10.1007/s13402-021-00587-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
675 Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, Huang XF, Chen SY. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun 2020;11:1395. [PMID: 32170083 DOI: 10.1038/s41467-020-15229-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
676 McCord R,